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Resumo 
 
 
A incidência mundial de cancro é elevadíssima, estima-se que um em cada cinco 
de nós irá morrer como consequência desta doença. Um estudo fei to  à escala 
global  demonstra que ex is tem 14.1 milhões de casos por ano, resultando em 8,2 
milhões de mortes. Em Portugal, o cancro é a segunda principal causa de morte, a seguir 
às doenças do aparelho circulatório, em particular o AVC (acidente vascular cerebral). 
Apesar de se encontrar no grupo restrito de tumores malignos mais facilmente 
detetáveis, o melanoma em fases mais avançadas da doença, é a forma mais mortal de 
cancro da pele que conduz a um tempo médio de sobrevivência bastante reduzido.  
Do ponto de vista clínico, apesar de existirem pacientes em fases iniciais que 
poderão ser tratados com sucesso através de cirurgia, em fases mais avançadas a 
aquisição de resistência à quimioterapia continua a ser um problema bastante comum.  
É imperativo encontrar alternativas de tratamento e melhores métodos de diagnóstico 
para o combate a esta doença.  
A medicina personalizada assume-se cada vez mais como uma excelente 
alternativa aos tratamentos convencionais. Uma vez que o cancro é uma doença bastante 
heterogénea, a medicina personalizada exige um conhecimento bastante profundo e 
especifico de cada paciente para que o tratamento possa ser aplicado de uma forma mais 
individual, ou seja, será necessário ao nível do diagnóstico, uma capacidade de 
hierarquizar pacientes com base no êxito perante a resposta ao tratamento com um 
fármaco que seja específico, por oposição às terapias convencionais. Prevê-se então uma 
mudança de paradigma no tratamento de cancro: dos agentes citotóxicos mais 
convencionais, até aos agentes mais específicos, concebidos com base nas 
especificidades de cada tipo de célula cancerígena. Com base neste pressuposto, é 
necessária a identificação e validação de novos alvos terapêuticos.  
O desenvolvimento de novas técnicas de biologia molecular tem alterado a 
maneira como nós entendemos a origem do cancro. Estudos “large-scale” ou “image-
based”, permitem interpretar os diferentes fenótipos resultantes de alterações químicas, 
genéticas ou epigenéticas pertencentes a cada tipo de tumor. Desta forma é possível 
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compreender as inúmeras vias moleculares orquestradas por diferentes genes, que dão 
origem controlam e regulam diferentes tumores. 
Numa célula normal, uma via de sinalização é desencadeada quando uma 
molécula (sinal) se liga a um recetor extracelular. É ativado então uma cascada 
bioquímica de eventos, evolutivamente conservados. O fim de uma via de sinalização 
passa pelo núcleo, cujo objetivo fundamental passa pela transcrição de genes que 
controlam diversos tipos de processos celulares fundamentais. Numa célula tumoral, 
algumas destas vias moleculares encontram-se alteradas. A partir de screens genéticos, é 
possível identificar as mutações responsáveis pela desregulação de genes e 
consequentemente das proteínas constituintes destas vias. As principais vias de 
sinalização alteradas em melanoma são a PI3K/AKT/m-TOR (principais membros 
alterados: PTEN (Phosphatase and tensin homolog) - 15–50% deletado, mutado ou 
silenciado; PI3K (Phosphoinositide 3-kinase) - 6% mutado; recetores membranares - 
10%–20% constitutivamente ativados e AKT (Protein kinase B) - 60% amplificado ou 
ativo), as via MAPK (Mitogen-activated protein kinase), também conhecida como via 
MEK/ERK (principais membros alterados: RAS (20%) e B-RAF (60%)).  
Outro membro com enorme relevo da via PI3K é o gene tribbles2. Para além de 
funcionar como um oncogene, tem sido descrito também como biomarcador para 
melanoma, característica que permite distinguir e avaliar se um paciente tem ou não 
desenvolvido este tipo de tumor. Quando expresso, TRIB2 assume também importante 
destaque na resistência ao tratamento com alguns fármacos e drogas anti tumorais, 
nomeadamente drogas que atuam ao nível da via PI3K. Tendo em conta todos estes 
fatores, questionamos se esta proteína também desempenha um papel importante no 
mecanismo de resistência criado após a administração de agentes inibidores de outro 
elemento desta via, m-TOR. Outra via de sinalização frequentemente alterada em 
melanoma é a via MEK/ERK. Para além disso trata-se de uma via alternativa à via PI3K, 
pelo que testamos a hipótese de que TRIB2 também regula a resistência a inibidores 
MEK. Examinámos o impacto da sobre expressão de TRIB2 ao nível celular, proteico, 
RNA e de DNA, na presença de inibidores proteicos MEK ou mTOR. 
Tendo como ponto de partida resultados anteriores do nosso laboratório, em que 
foi possível demonstrar que TRIB2 confere resistência a diferentes tipos de agentes 
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quimioterapêuticos convencionais, assim como a inibidores de PI3K, começamos por 
averiguar se TRIB2 também confere resistência em células tratadas com inibidores m-
TOR. Foram criadas linhas isogénicas celulares, com o intuito de formar células com 
diferentes concentrações proteicas: elevados ou baixos níveis de TRIB2. 
 Após o tratamento com rapamicina, um potente inibidor do complexo mTORC1, 
verificou-se que apenas as células que contêm elevados níveis de TRIB2, resistem ao 
tratamento com este tipo de inibição. 
De seguida, submetemos de novo linhas isogénicas ao tratamento com um 
inibidor tanto do complexo mTORC1 como do mTORC2, TORIN1. Os resultados são 
bastante claros e revelam que TRIB2 não confere qualquer tipo de resistência, quando 
mTORC2 é inibido. 
Quando as células que sobre expressam TRIB2 são tratadas com BAY 766, um 
poderoso inibidor MEK, são criados mecanismos de evasão e estas células resistem. O 
mecanismo fundamental pelo qual as células ultrapassam a resistência, é determinada 
pela interação entre MEK e TRIB2 que formam um complexo proteína- proteína. Estes 
resultados são enfatizados quando os sinais imunofluorescentes de TRIB2 e MEK de 
células resistentes se sobrepõem. Observamos também que a ativação da via de 
sinalização MEK/ERK regulada por TRIB2, reprime a ação de FOXO3a um importante 
fator de transcrição. Por outro lado, os nossos resultados apontam para que TRIB2 leva a 
um aumento de afinidade de NF-κB se ligar ao promotor, sugerindo que a sua 
concentração aumenta no interior do núcleo destas células resistentes a inibidores MEK. 
De seguida, testou-se a ativação da via PI3K, verificando se a proteína AKT se 
encontrava fosforilada. Os resultados são semelhantes para todas as linhas celulares, 
ocorrendo fosforilação de AKT. Averiguamos de que forma esta proteína seria ativada, e 
verificou-se que a ativação de AKT ocorre pela fosforilação do resíduo serina na posição 
473, sempre que as células sobre expressam TRIB2. 
Como é sabido, mTORC2 desempenha um papel importante na ativação de AKT 
através da fosforilação da serina 473. Um dos elementos fundamentais deste complexo é 
a proteína RICTOR. Procedemos ao seu knock down, e a resistência criada na presença 
de diferentes drogas (BEZ235, BAY236 e BAY439), é perdida. O mesmo resultado é 
obtido quando o Knock down é feito para FOXO3a. 
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O melanoma, em fases mais evoluídas da doença (estádio IV), tem-se revelado 
como uma das formas mais mortais de cancro. É imperativo que se consiga encontrar 
novas formas de combate a este tipo de doença com contornos tão trágicos. A 
importância biológica deste projeto prende-se exatamente com esta necessidade: tentar 
perceber qual o papel da proteína TRIB2, do ponto de vista molecular, descrita 
anteriormente como um biomarcador para melanoma no mecanismo de resistência a 
múltiplas drogas. 
Após o término do projeto, foi possível verificar que TRIB2 confere resistência, 
em diferentes linhas celulares após a administração de drogas que inibem a estrutura 
proteica mTOR. TRIB2 funciona como uma molécula ativadora de AKT, uma proteína 
que desempenha um papel fundamental na via de sinalização PI3K/AKT/mTOR, uma 
das vias mais alteradas em melanoma. Por sua vez um dos ativadores moleculares de 
AKT é o complexo mTOR. Verificámos que quando TRIB2 é sobre expresso, a ativação 
de AKT acontece apenas através do complexo 1 de mTOR e não pelo complexo 2. Indo 
um pouco mais fundo nesta análise concluímos que AKT é ativado por mTOR1 que tem 
a capacidade de fosforilar o resíduo serino na posição 473, um dos requisitos para que 
ocorra a ativação completa de AKT. 
Uma outra via de sinalização, que se encontra ativa em melanoma é a via MAPK, 
mais em concreto a via MEK/ERK.  À imagem do que acontece aquando a 
administração de diferentes inibidores, TRIB2 exerce um papel chave no mecanismo de 
resistência a inibidores MEK. Em células resistentes, TRIB2 forma um complexo 
proteína-proteína com MEK, que conduz a ativação de ERK e por consequência de toda 
a via. Esta ativação, culmina com a presença de vários fatores de transcrição no núcleo, 
como é exemplo NF-κB, conduzindo à transcrição de diferentes genes fundamentais nos 
processos de evasão, crescimento celular e proliferação. 
 
 
Palavras-chave: Melanoma; inibidores MEK; inibidores mTOR; fármaco-
resistência; TRIB2 
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Abstract 
 
 
Malignant melanoma is the deadliest form of skin cancer that leads to a median 
survival time of only 6 to 9 months. Besides the patients in early stages that could be 
successfully treated by surgery alone, actually, there is no efficient diagnostic 
procedure. It is imperative to find alternatives and better methods of diagnosis for 
metastatic melanoma. Acquisition of resistance to chemotherapy agents, namely cytotoxic 
drugs such as dacarbazine, remains a major problem in melanoma therapy. 
Since TRIB2 (tribbles2) protein has recently been implicated as a biomarker for 
melanoma, and as a mediator in the process of resistance to conventional 
chemotherapeutics or PI3K (Phosphoinositide 3-kinase) inhibitors, we hypothesised that 
resistance to the inhibition of different components of this and other signalling pathways 
such as mTOR (mammalian target of rapamycin) and MEK (MAPK/ERK Kinase) is 
mediated by TRIB2. 
In this study, we examined the impact of ectopic expression of TRIB2 in the 
presence of mTOR or MEK inhibitors. 
We demonstrated that in the presence of rapamycin, a potent inhibitor of mTORC1 
(mammalian target of rapamycin complex 1 or mechanistic target of rapamycin complex 
1), TRIB2 confers resistance to this kind of treatment. However, when we exposed cells 
to a mTOR2 inhibitor, TORIN1, resistance is not observed. We demonstrated that 
TRIB2 acts as an adaptor, recruits the mTOR complex 1 that phosphorylates AKT (also 
known as Protein Kinase B, PKB) on residue Serine 473. 
Furthermore, we investigated the effect of TRIB2 expression, when cells where 
exposed to pharmaceutical inhibition of MEK. We found that TRIB2 expression protects cells 
against the effect of the MEK inhibitor BAY 766. We have seen that TRIB2 and MEK co-
localize, interact and form a protein-protein complex. We also observed that the inhibition 
of MEK/ERK and PI3K pathways regulated by TRIB2, represses FOXO3 (Forkhead box 
O3a) a binding to p27 promoter, a well-known and studied transcription factor. On the 
other hand, high levels of TRIB2 leads to an increase of NF-κB (factor nuclear K B) 
affinity for promotor. NF-κB enhances the transcription of different genes crucial for 
melanoma cells proliferation and survival. 
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This study suggests that TRIB2 is a meaningful component of a drug resistance 
mechanism in melanoma cells. This molecular process determines and modulates 
important cell decisions which include cell growth, proliferation and survival. 
 
 
 
Keywords: Melanoma; MEK inhibitors, drug resistance; mTOR inhibitors; TRIB
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CHAPTER 1. INTRODUCTION 
1. Cancer 
 
Cancer is a leading cause of death and it is estimated that about one in five of us will 
die as a consequence of cancer. The worldwide incidence of cancer is extremely high, a 
2012 study revealed that there are 14.1 million cases per year, resulting in 8,2 million 
deaths. It is also estimated that there are 32,6 million people living with cancer (within 5 
years of diagnosis). 1 
The evolution of molecular biology techniques has changed the way we see the 
origin of cancer. Nowadays, the focus of carcinogenesis studies has shifted from the 
identification of gene mutations to understanding the pathways that these genes control. 
This paradigm shift has suggested that tumorigenesis, at the molecular level, results after 
several genetic alterations that have occurred within the cell. It is a multistep process, in 
which every gene affected encode proteins with different functions.2,3 
In this way, the most mutations are observed in genes related with cell growth and 
proliferation (including oncogenes such as RAS, cMYC and SRC), tumour suppressor 
genes that inhibit cell proliferation (p53, RB and FOXO´s), control of apoptosis (p53, 
FOXO´s and BCL-2), cell-contact inhibition (E-CADHERIN), promotion of survival 
(telomerase and PI3K/AKT) and stability genes that are responsible to repair mistakes in 
genome made during normal DNA replication or induced by exposure to environmental 
factors (mismatch repair, nucleotide-excision repair and base-excision repair genes).2 
A cell needs to overcome a number of mechanisms in order to become cancerous. 
This theory proposes that cells, to achieve transformation, must activate some 
proliferative signal transduction, evade the growth suppression mechanisms, resistance to 
apoptosis, enable replicative immortality, induce angiogenesis, activate invasion and 
promote metastasis.4,7 
Recently, two other hallmarks were added: reprogramming of energy metabolism 
and evading immune destruction.8 Acquisition of drug resistance and avoidance of 
oncogene (it will be discussed in next sections) and inducing of senescence are also 
another important features in tumour development. 
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2. Melanoma 
2.1 A clinical perspective 
 
In the last 50 years melanoma has risen faster than any other cancer type and unlike 
other kind of cancers, melanoma incidence is not strongly dependent on age, and is one 
of the most common causes of cancer deaths between the ages of 20–35. It remains one of 
the cancers most resistant to treatment.9 Melanoma provides one of the best sources to 
study the relationship between environmental factors and cancer cells. It arises within any 
anatomic place that contains normal pigment cells (neural crest-derived melanocytes), 
located on the basement membrane of epithelial surfaces. The main function of 
melanocytes is the synthesis, storage, and transfer of melanin pigments to surrounding 
epithelial cells9. 
2.2. Diagnosis 
 
Histological patterns have been well described. Microscopic features that correlate 
with clinical subgroups (including superficial spreading melanoma, nodular melanoma, 
acral lentiginous melanoma (it is the most common subtype of melanoma in people with 
darker skins.), and lentigo malignant melanoma (also known as Hutchinson melanotic 
freckle., lentigo maligna has a lower rate of transformation to invasive melanoma than the 
other forms)) have been thoroughly codified. As an example, cutaneous lesions detected 
as little as 1 mm in Breslow thickness could have microscopic evidence of lymph node 
metastasis which, when present, confers a significantly increased risk for metastasis.910 
The traditional Clark model is a multi-step system to predict the progression of 
melanoma. Several models that try to explain the genetic basis of melanoma development 
and progression are based on this Clark model. It also predicts that the acquisition of a 
BRAF mutation can be a founder event in melanocytic neoplasia. 
It emphasizes the stepwise transformation of melanocytes to melanoma, from the 
formation of nevi to the subsequent development of dysplasia, hyperplasia, invasion, and 
metastasis 9 (Fig.1.1). 
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Melanoma progression can also be classified according to different stages of the 
disease in a clinical grading system (stages 0, I, II, III, and IV).11 
2.3 Clinical Grading System 
 
Melanoma disease progression is typically evaluated using the American Joint 
commission on Cancer (AJCC) system (Table 1.1). It is a four stage system that 
incorporates tumour thickness, presence of ulceration and how widespread the melanoma 
is in a patient (if it has spread to nearby lymph nodes or any other organs). 
The fact is that melanoma diagnosis is very much based on the professional’s 
experience and on complex laboratory tests, being a very subjective factor. Therefore, 
more accurate ways to diagnose and stage this disease are being searched for. 
 
. 
 
 
 
Table 1.1-Malignant melanoma staging system approved by AJCC11 
Figure 1.1-Classification of melanoma development55  
Melanoma can be classified according to the Clark´s model based on the level of 
invasiveness: I-Epidermis (normal); II to IV- dermis (Nevus, RGP, VGP,); V- 
subcutaneous tissue (metastatic melanoma). The Breslow approach considers the 
millimetres of invasion depth, ranging from 0 to 2mm. (representation of a vertical 
section of skin) 
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2.4. Conventional Therapies 
 
The standard therapy options for melanoma are surgery (surgical removal of the 
tumour and surgical excision margins based on Breslow’s tumour thickness) for non- 
metastatic tumours detected early, surgery, radiation, chemotherapy and supportive care. 
The median survival time for melanoma patients with stageIV melanoma ranges from 0.7 
to 5 months depending on age and performance status (how patients react to treatment).12 
The chemotherapeutic drugs used in the treatment of several tumours can be 
classified according to their function: DNA-modifying agents (nitrogen mustard, first 
used in a patient with lymphoma), anti-metabolites (5-fluorouracil (5-FU)), spindle 
poisons (paclitaxel), topoisomerase inhibitors (doxorubicin) and cytotoxicantibiotics 
(bleomycin). Some chemotherapeutic agents have activity in patients with metastatic 
melanoma, including dacarbazine (DTIC) which is an alkylating agent as well as the 
nitrosoureas, platinum analogs, vinca alkaloids (vinblastine), and the taxanes (paclitaxel). 
Numerous trials of single agents or combinations of chemotherapy have been performed, 
but DTIC remains the standard regimen and the most used chemotherapeutic agent for 
melanoma. The response rate observed with DTIC chemotherapy alone ranges from 15% 
to 25%, indicating that improved therapies are desperately required.12 
Although the clinical criteria for atypical nevi and traditional therapies have been 
useful in diagnose and improvement of treatment, they are not precise or highly 
reproducible and contain some pitfalls: for instance, only a small percentage of primary 
melanomas arise from nevi (10-20%)9and chemotherapy for advanced melanoma (stage 
IV) remains largely palliative with low survival rates after diagnosis.12Therefore, new 
therapy strategies are required. 
 
3. Molecular Pathways in Melanoma 
 
It is crucial to develop new strategies, so over the past 30 years, many groups have 
helped to decipher the complex genetic networks involved in melanoma proliferation, 
progression and survival and our understanding has significantly improved. Many of 
these oncogenic loci and pathways are being well studied and have become crucial targets 
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for pharmacological drug development. This continuous understanding of the disease can 
revolutionize the treatment of cancer.13,14 
In a normal cell, the general signalling can start when a signalling molecule binds 
to a cell receptor (extracellular signals). The signal molecule can be a growth factor, 
mitogens, hormones, neurotransmitters or cytokines. It can take place either through direct 
cell-cell contacts and cell-matrix interactions (integrins and cadherins) or through the 
action of secreted signalling molecules. Secreted signalling can be classified into 
endocrine, paracrine and autocrine signalling. In endocrine mechanism, hormones are 
carried through the circulatory system to act on distant target cells. In paracrine signalling, 
a molecule released from one cell acts locally to affect nearby target cells and in autocrine 
signalling, a cell produces a molecule to which it also responds. Then the signal is usually 
transmitted into a cascade of events evolutionarily conserved, that passes a message into 
the nucleus. Here, different transcription factors, such as FOXO3a, NF-KB, c-MYC, AP-
1, p53 and E2F1 for example, have the capability to enhance transcription. Different 
genes are transcribed controlling fundamental cellular processes such as proliferation cell 
growth, apoptosis, cellular energy production, cell transport or homeostasis10-15. In 
tumour cells, these pathways are modified and the scientific community has been 
performing high throughput genomic screens to identify many of the driver mutations 
responsible for malignancy. The dysregulation of these genes affecting upstream proteins 
like cell receptors or downstream proteins plays an important role in the development of 
melanoma.10,15Different studies suggest the involvement of pathways like Notch and 
WNT/βb-catenin 16,17. Our attention is directed towards the most mutated molecular 
signalling pathway implicated in melanoma development. MAPK pathway is the most 
important pathway in melanoma, and has been reported to be activated in over 80% of all 
cutaneous melanomas, making it the focus of many scientific studies in the melanoma 
field. The most common mutations are found in RAS (25%); B-RAF (70%). The second 
most important signalling axis is PI3K/AKT, with several of its members being mutated 
or modified are PTEN - 15–50% deleted, mutated or silenced; PI3K – 6% mutated;10%–
20% receptor-independent activated and AKT - 60% amplificated or activated. 
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3.1 RAS/RAF/MAPK molecular pathway 
 
Mitogen-activated protein kinase (MAPK) cascades are key signalling pathways 
involved in the regulation of cell proliferation, survival and differentiation being activated 
by a wide variety of receptors involved in growth and differentiation including receptor 
tyrosine kinases (RTKs), integrins, and ion channels. 20 
The ERK pathway is the best studied of the mammalian MAPK pathways, and is 
deregulated in approximately, one-third of all human cancers. 
The signalling cascade is triggered depending on the molecular stimuli (growth 
factors and mitogens), the scaffold of the pathway usually includes a set of adaptors (Shc, 
GRB2, Crk, etc.) linking the receptor to a guanine nucleotide exchange factor (SOS, C3G,  
Figure 1.2-MAPK signalling pathway.54 
Although there are more pathways as shown in this figure, the three most significant 
arms of the mitogen-activated protein kinase (MAPK) pathway are ERK (extracellular 
signal-regulated kinase), JNK (c-Jun N-terminal kinase) and p38. They can be activated 
through different stimulus such as growth factors, integrins and interleukines . The 
three-tiered kinase dynamic cascade leads to activated MAPKs entering the nucleus to 
trigger immediate early gene and transcription factor activation for cellular responses 
such as cytokine production, apoptosis, cell proliferation and migration. 
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etc.). Then, the signal is transduced to small GTP-binding proteins (RAS). RAS proteins 
(H-, K- and N-Ras) function as a GDP/ GTP-regulated switch. GDP/GTP cycling is 
regulated by guanine nucleotide exchange factors (RAS GEFs; e.g., Sos) that promote 
formation of active RAS-GTP, whereas GTPase-activating proteins (GAPs; e.g., NF1 
neurofibromin) stimulate GTP hydrolysis and formation of inactive RAS-GDP. In normal 
cells, Ras is bound to GDP and inactive. Extracellular stimuli cause transient formation of 
the active Ras. Activated Ras-GTP binds to downstream effector targets, of which the Raf 
kinases are the best characterized. The core unit of the cascade of these three kinases: is 
composed by MAPKKK (Raf-1, B-RAF and A-RAF)) that activates MEK1/2 by 
phosphorylating serines 218 and 222 in the activation loop, MAPKK (MEK1/2), and 
MAPK (ERK). An activated ERK dimer can both regulate targets in the cytosol and 
phosphorylate a variety of transcription factors in the nucleus regulating gene expression. 
(Fig. 1.2)20–23 
 
The second most important molecular network involved in melanomagenesis is the 
PI3K/AKT/FoxO signalling axis. There is growing evidence that activation of this 
pathway plays a significant role in melanoma, frequently in the setting of concurrent 
activation of RAS-RAF-MEK-ERK signalling. This evidence includes the identification 
of genetic and epigenetic events that activate this pathway in melanoma cell lines. 
 
3.2. PI3K/AKT/FoxO signalling axis 
 
Phosphoinositide 3-kinase (PI3K) is a major component of the signalling pathway 
and can be activated by receptor tyrosine kinases (RTKs) like HER2 and EGFR or G 
protein-coupled receptors. The GTPase RAS can also recruit and activate PI3K through 
direct binding.18,19 
PI3K is a heterodimer with a catalytic subunit p110 and a regulatory subunit p85 
that regulates many normal cellular processes including cell proliferation, survival, 
growth, and motility. PI3K catalyses the production of the lipid second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane phosphorylating 
phosphatidylinositol-4,5-bisphosphate (PIP2) at the 3′ position on its inositol ring. Pip3 
is now able to recruit other downstream molecules such as AKT and PDK1 via their 
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pleckstrin-homology (PH) domains.18,19 In an opposite way there is a phosphatase 
PTEN that converts PIP3 back to PIP2 acting as a tumour suppressor (Fig.1.4). 
 
 
AKT can be phosphorylated at two critically conserved residues (threonine 308 and 
serine 473) and only reaches its full activity if both are phosphorylated. The kinase 
phosphoinositide- dependent kinase 1 (PDK1) targets the threonine 308 residue whereas 
the serine 473 residue is phosphorylated by the Mechanistic Target of Rapamycin 
Complex 2 (mTORC2). When AKT is fully activated, regulates a wide range of different 
targets with different cell functions (Fig.1.3). 
Figure 1.3-The PI3K/Akt/mTOR signaling pathway.18 
This pathway is up-regulated in melanoma via either direct upstream stimulation 
(growth factor receptors and their ligands) or indirect activation via cross-talk with 
RAS. The crucial step in this pathway is the AKT full activation that can regulate 
members of the apoptotic pathway: inhibit Bad, and FOXO transcription factors and 
activates NF-kB and CREB that regulate anti-apoptotic genes. It inhibits GSK3β 
(Glycogen synthase kinase-3) responsible for the degradation of β-catenin resulting in 
cell cycle progression. 
The activation of mTOR leads to regulation of cell growth by controlling mRNA 
translation, ribosome biogenesis, autophagy, and metabolism. 
AKT also targets survival and cell cycle regulation. AKT phosphorylates Mdm2 
that controls the levels of p53 in the cell. 
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3.3. Mechanistic target of rapamycin (mTOR) 
 
The mechanistic target of rapamycin (mTOR) protein is a 289-kDa 
serine/threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K)-related 
kinase family and is conserved throughout evolution. It has emerged as a critical growth-
control node, receiving stimulatory signals from Ras and PI3K downstream from growth 
factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen 
availability Aberrant mTOR signaling is involved in many disease states including 
cancer, cardiovascular disease, and diabetes. It is present in two distinct multi-protein 
complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)67 (figure 
1.4)  
mTORC1, is composed of regulatory-associated protein of mTOR (Raptor), 
mammalian lethal with Sec13 protein 8 (mLST8, also known as GbL); proline rich AKT 
substrate 40 kDa (PRAS40); and DEP-domain-containing mTOR-interacting protein 
(Deptor) and is inhibited by rapamycin. After entering the cell, rapamycin binds to 
FK506-binding protein of 12 kDa (FKBP12) and interacts with the FKBP12- rapamycin 
binding domain (FRB) of mTOR, thus inhibiting mTORC1 functions. mTORC1 is 
known for its role in regulating cell growth and proliferation through modulation of 
protein synthesis. The AKT promotes cell growth (i.e., accumulation of cell mass) 
predominantly when activation of complex 1 of the mammalian target of rapamycin 
(mTORC1) occurs Recent research has identified novel mTORC1 cell signalling 
mechanisms that modulate mitochondrial biogenesis, hypoxia signalling and cell cycle 
progression. 
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The second complex, mTOR complex 2 (mTORC2), is composed of mTOR, 
RICTOR, GβL, Sin1, PRR5/Protor-1, and DEPTOR. It ca be inhibited with BEZ235 and 
it is not sensitive to rapamycin. Functions for Mtorc2 is still unclear. However, the first 
function ascribed to mTORC2, based on the previously known function of TORC2 in 
yeast, was the regulation of the actin cytoskeleton. Knockdown of mTORC2-specific 
components in cultured cells results in alteration of the actin cytoskeleton68. AKT was 
identified as a mTORC2 substrate, it was found that phosphorylates Ser473 in the 
hydrophobic motif of AKT66. Although earlier knockdown studies of RICTOR also 
showed reduced phosphorylation of Thr308 in the activation loop, further studies in 
knockout mice suggested that phosphorylation of Thr308, by phosphoinositide-dependent 
kinase 1 (PDK1), does not depend on prior Ser473 phosphorylation66,67 
3.4. Transcription Factors 
        3.4.1. Nuclear factor Kappa B (NF-κB) 
 
Increased expression of pro-inflammatory and proangiogenic factors is associated 
with aggressive tumour growth and decreased survival of patients with cancer. In 
Figure 1.4-mTOR complexes69. 
mTOR nucleates two different complexes: mTOR complex 1 (MTORC1) on the left and 
mTOR complex 2 (mTORC2) on the right. AKT is activated by mTORC2, through 
phosphorylation of Ser 473. 
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particularly, recent genetic and cancer genome studies, support the involvement of 
nuclear factor Kappa B (NF-κB) transcription factors, and the signalling pathways that 
control its activity, in human cancer32,33. 
Nuclear factor Kappa B (NF-κB) was first discovered in 1986 as a nuclear factor 
that binds to the enhancer element of the immunoglobulin kappa light-chain of activated 
B cells34.This transcription factor has a key role in many physiological processes such 
as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. 
It has become clear that aberrant regulation of NF-κB leads to tumour progression, as 
well as to resistance to chemotherapy and radiotherapy35. 
The genes regulated by NF-κB (NF-κB-dependent transcription) are not only tightly 
controlled by positive and negative regulatory mechanisms but also closely coordinated 
with other signalling pathways. The list of NF-κB-dependent target genes can be further 
extended to regulators of apoptosis (antiapoptotic Bcl family members and inhibitor of 
apoptosis proteins/IAPs), proliferation (cyclins and growth factors) genes such IκBα, 
p105, or A20 that generate auto-regulatory feedback loops in the NF-κB response. Other 
NF-κB target genes are central components of the immune response, e.g., immune 
receptor subunits or MHC molecules. Inflammatory processes are controlled through NF-
κB-dependent transcription of cytokines, chemokines, cell adhesion molecules, factors of 
the complement cascade, and acute phase proteins This intricate crosstalk is crucial to 
shaping the diverse biological functions of NF -κB into cell type– and context-specific 
responses36. 
 
3.4.2. Forkhead transcription factors of the O class (FOXOs) 
 
One of the most important AKT and ERK targets are the mammalian forkhead 
transcription factors of the O class (FoxOs) that include FoxO1, FoxO3, FoxO4 and 
FoxO6. 28–30 FOXO family members have overlapping but different patterns of expression 
of genes that influence cell proliferation, survival, metabolism and response to stress 
indicating that they may have redundant as well as distinct functions. These proteins 
contain multiple levels of regulation including phosphorylation, acetylation/deacetylation, 
ubiquitination and protein–protein interactions.28,30 They were first reported in fusion 
genes in human soft-tissue tumours and leukemias. It was observed that three of the four 
known FOXO genes were found at chromosomal translocation breakpoints in this type 
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of tumours.  Nowadays it is known that FOXO factors are deregulated in several 
tumour types including breast cancer, prostate cancer, glioblastoma, rhabdomyosarcoma, 
melanoma and leukemia. Interestingly, these translocations occur at the identical 
position, immediately N terminus to the recognition helix (H3) of the FOXO family 
members and these fusions are no longer controlled by AKT and are constitutively 
retained in the nucleus. 
Another role for FOXO3a inactivation in cellular transformation can also be inferred 
from the fact that FOXO3a negatively regulates cell survival and cell cycle progression 
in mammalian cells and that FOXO family members are regulated by the PTEN tumour 
suppressor. Furthermore, nuclear exclusion of FOXO3a correlates with expression of 
IKKb or phosphorylated AKT in many primary tumours. It is a good candidate to 
biomarker, linking poor survival of the patients with breast tumours. 
In response to stress stimuli or to nutrient deprivation, FOXO3a has been found to 
interact with the tumour suppressor p53 in vitro. Given that FOXO3a shares similar target 
genes including p21, GADD45, WIP1 and PA26 with p53, it suggests that these two 
proteins may coordinate mechanisms of tumour suppression.28,30,31 FOXO3a is known as 
a tumour suppressor and activation of FOXO3a factors by mutation of the 
phosphorylation sites (thereby restricting the localization of the FOXO proteins to the 
nucleus) leads to cell-cycle arrest or cell death. Therefore, FOXO3a represent an 
interesting potential target to develop novel therapeutic approaches for cancer28 
 
4. Biomarkers 
 
Biomarkers are tumour related factors that correlate with tumour biological 
behaviour and patient prognosis. In a very general sense, a biomarker describes any 
measurable diagnostic indicator that is used to assess the risk or presence of disease. For 
example, current methods of detection, prognostication, and monitoring of melanoma 
focus on clinical, morphologic, and histopathologic characteristics of measurable tumour, 
based on the conventional American Joint Committee on Cancer (AJCC) staging system 
are Clark and Breslow tumour thickness, presence of ulceration and extent of nodal 
involvement for primary cutaneous melanoma, and site of metastases for distant metastatic 
disease.55 Although this information provides some insight into disease behaviour and 
outcome, melanoma is still an unpredictable disease. It should be a molecule that can be 
TRIB2 confers resistance to MAPK and mTOR1 inhibitors 
CHAPTER 1. INTRODUCTION 
 
13 
 
measured in blood or other body fluid that are accessible, minimally invasive to the patient 
and is low cost. Nowadays, the only melanoma biomarker being incorporated in the 
prognostic classification system established by the AJCC was lactate dehydrogenase 
(LDH).56,57 
Given the hypoxic environment of melanoma cells with resultant inability to 
produce adenosine triphosphate from glucose through oxidative phosphorylation, LDH 
catalysis the conversion of pyruvate to lactate when oxygen supply is low or absent. It is 
not a secreted enzyme; thus, an elevated serum level is thought to be secondary to spillage 
of LDH when melanoma cells outgrow their blood supply. Besides LDH, other circulating 
tumour markers in melanoma are being tested (melanoma inhibitory activity, lipid bound 
sialic acid, neuron specific enolase, TA90 immune complex, S-100B protein, 5-S-
cysteinyldopa, tyrosinase, cytokines, metalloproteinases).58 
Modern personalised medicine intends to use individual molecular markers and 
patterns of markers to subdivide traditional tumour stages into subsets that behave 
differently from each other, based on current molecular information which indicates that 
melanoma should be viewed as a heterogeneous group of disorders with molecularly 
distinct defects in important cellular processes that include cell cycle regulation, cell 
signalling, cell adhesion, cell differentiation and cell death. Advances in genomics, 
proteomics, molecular pathology, technologies such as mass spectrometry, protein and 
DNA arrays, combined with our understanding of the human genome, have generated 
many candidate biomarkers of potential clinical value. 37These prognostic and therapeutic 
markers might help to define molecular targets involved in different pathways, in order to 
achieve improvements in the clinic. 
 
4.1 TRIB2  
 
TRIB2 is a member of Tribbles (Trib) gene Family. The tribbles gene was 
identified first in Drosophila mutational screens for genes that control cell proliferation 
and migration. The members of this family share a TRIB domain, which is homologous 
to protein serine-threonine kinases, but lacks the active site lysine lacking a catalytic 
activity. These proteins function as adaptors in signalling pathways, instead of direct 
phosphorylation and interact with various transcription factors including ATF4, p65, CtIP. 
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MAPKK and COP1 are also known to interact with TRIB2. They are also involved in a 
series of non-neoplastic disorders including metabolic, neurological diseases and cancer. 
TRIB2 is a FOXO repressor that contributes to the maintenance of oncogenic 
properties by cells in melanoma such as growth and survival.38–40 The TRIB2 domain(s) 
responsible for oncogenic activity are currently unknown but the integrity of the KD is 
essential for cell proliferation and survival. Mutations in this domain significantly 
interferes with these activities. 39 TRIB2 is associated with high expression in melanoma 
and this high expression will induce the repression of FOXO family members, that 
are known to play a central role in diverse physiological processes including cellular 
energy storage, growth, and survival and protect the organism from stress and aging28. 
Recently, TRIB2 was found to be a melanoma biomarker that reflects the stage and 
progression of melanoma and as well the predicting the clinical outcome following 
patient treatment 52 
TRIB proteins share four motifs: a pseudo kinase domain/TRIB domain (divergent 
kinase region with undetermined catalytic activity), a catalytic loop, a COP1 site used to 
direct key target proteins to the proteosome , and a MEK1 site that binds and modulates 
MAPKK kinase activity 40 (Fig.1.5) 
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Figure 1.5–Different motifs within the TRIBBLES protein structure.40 
The tribbles family of genes encodes pseudokinase proteins that share a divergent kinase 
region (Trib domain), a catalytic loop, a COP1 site used to direct key target proteins to 
the proteosome for degradation, and (3) a MEK1 site that binds and modulates MAPKK 
kinase activity. These proteins are highly conserved in evolution as we can see through the 
similarity between species (Human, Mouse and Drosophila). 
 
The role of TRIB2 in the development of several diseases has been described in the 
literature: TRIB2 negatively regulates WNT signalling in liver, its over expression 
induces acute myelogenous leukemia in mice through inactivation of C/EBPα, TRIB2 is 
over expressed and often amplified in lung cancer and the down regulation of the tumour 
suppressor gene FOXO3a is mediated by TRIB2 in human melanoma cells38–40 
 
5. Melanoma Treatment 
 
Cancer medicine is increasingly moving toward a new era of personalized 
diagnostics and therapeutics. The identification and validation of tumour relevant 
molecular targets in the different pathways discussed previously, is the first step in the 
discovery of these therapeutic compounds. Targeted therapeutic agents, includes small 
molecules or monoclonal antibodies that interact with a molecular target. 
From 2011 until now, the U.S. FDA has approved seven novel agents, such as 
BRAF-inhibitors (vemurafenib 2011, dabrafenib 2013), MEK-inhibitors (trametinib 
2013), anti-PD1 antibodies (nivolumab 2014, pembrolizumab 2014), anti-CTLA-4 
antibody (ipilimumab 2011), or peginterferon-alfa-2b (2011) In the recent years, the use 
of traditional chemotherapy for metastatic melanoma has given no evidence for survival 
benefit. Recent advances have led to the first clinical trials in history where treatment has 
been associated with a survival benefit16. A phase III trial compared vemurafinib, BRAF 
inhibitor specific to melanomas harbouring the BRAF V600E, to dacarbazine, a 
traditional chemotherapeutic drug (alkylating agent), in patients with previously untreated 
melanoma. The vemurafenib arm demonstrated superior overall survival (86% versus 
64% at 6 months) and progression-free survival (median 5.3 months versus 1.6 months 
when compared to dacarbazine alone).51 
Another two different phase III trials, shows that the median progression-free 
survival was 5·1 months for dabrafenib and 2·7 months for dacarbazine.52 
Trametinib (GSK1120212, GlaxoSmithKline Pharmaceuticals) is an orally 
available, small-molecule, selective inhibitor of MEK1 and MEK2. In 2013, after 
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treatment cutaneous squamous cell carcinomas were not observed and the median 
progression-free survival was 5·7 months for these patients.53 
In table 1.2 is represented the bulk of agents used to target different pathways in 
melanoma. The majority of these compounds like PI3K/AKT or MEK/RAF inhibitors, 
are still in experimental development or clinical trials, but they seem to be very promising 
in melanoma treatment. However, some of this drugs have failed in clinical trials or the 
tumour has developed mechanisms of resistance by deregulation of other pathways by 
other oncogenes, suggesting that other points might be more promising to target, and the 
mechanisms of resistance must be discovered.  
 
5.1 mTOR inhibitors 
 
The mechanistic target of rapamycin (mTOR) is a critical kinase in the regulation of 
gene translation and has been suggested as a potential target to treat melanoma. So, over 
the past few years a number of components of the PI3K/mTOR pathway have been the 
subject of intense drug discovery both in pharmaceutical companies and in academic 
research. Rapamycin is one of the most efficient inhibitors being tested. It is an allosteric 
inhibitor of mTOR, and was approved as an immuno-suppressant in 1999. Other drugs 
such as rapamycin analogues or rapalogs (Temsirolimus- (CCI-779)), competitive 
inhibitors (PP242)   and other mTOR inhibitors like Everolimus (RAD001), are being 
developed and tested. 
Rapamycin and rapalogs have the interesting characteristic that are very specific for 
mTORC1 complex. Since it is known that PI3K regulates mTOR activity, most of the 
non-rapalog mTOR inhibitors described to date in the scientific literature were developed 
to inhibit other enzymes, especially class I PI3Ks. As an example we have BEZ235, used 
in our experiments and GSK2126458. These two compounds are known to dual inhibit 
PI3K and mTOR. 
A new generation of ATP-competitive inhibitors that directly target the mTOR 
catalytic site, with potent mTOR inhibition are now being tested in early clinical trials. 
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5.2 MEK inhibitors 
 
MEK1 and MEK2 are homologous dual specificity kinases that share ERK as their 
only known catalytic substrate, making MEK an appealing target for cancer drug 
development. Besides the ATP-binding region that is also present in other proteins, MEK 
contains a hydrophobic allosteric pocket adjacent to the ATP-binding site that is specific 
for this kinase allowing the design highly selective inhibitors of MEK. Another important 
fact is that unaffected PI3K-AKT status may contribute to increased sensitivity to MEK 
inhibitors in melanomas whose MAPK pathway is activated through oncogenic mutations 
in BRAF gene.43 One of the promising MEK inhibitors is AZD6244. In vitro studies 
reported that the majority of cell with mutations in Raf gene are sensitive to this drug. In 
the other way, none of the resistant cell lines possessed a B-Raf mutation, suggesting that 
cell lines containing mutant B-RAF are dependent on MEK activity and therefore 
sensitive to MEK inhibition. Another study suggests the use of MEK inhibitors in 
combination with PI3k inhibitors, in the treatment of cancers with coexisting PIK3C and 
KRAS mutations44  
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Pathway Mol. Target drug    Mode of action                             Ref.       
PI3K/Akt c-kit Imatinib                                  
PI3K/Akt PI3K ZSTK474an ATP-competitive inhibitor that inhibits 
   all four PI3K isoforms                                   40 
PI3K/Akt PI3K/mToR BEZ235 Kinase inhibitor(PI3K and mTor)                 40 
PI3K/Akt  GSK2126458 A small-molecule pyridylsulfonamide 
   inhibitor of PI3k                                            40 
PI3K/Akt  BYL719 PI3K inhibitor                                                40 
PI3K/Akt PI3K/mToR CCI-779 An ester analog of rapamycin. Inhibits           
  (Temsirolimus) mTOR                                                            41 
PI3K/Akt PI3K/mToR RAD001 Inhibitior of mTOR                                        2 
  (Everolimus)  
PI3K/Akt akt Isoselenocyanates Small molecule that inhibits akt 
  (ISC-4)  
MAPK/ERK Raf-1 Bay439006 Competes with ATP 
 
MAPK/ERK 
 
V600Eb-Raf 
 
Sorafenib 
 
inhibits cell proliferation 
 
 
MAPK/ERK 
 
 
V600Eb-Raf 
(BAY43-9006) 
 
PLX4032 
and vascular development 
 
Inhibits directly V600Eb-Raf 
  (Vemurafenib)  
MAPK/ERK  GSK2118436 inhibitor of B-raf                                            40 
MAPK/ERK V600Eb-Raf (dabrafenib)  
MAPK/ERK Mek AS703026 small-molecule inhibitor of MEK1 and 
   MEK2 
MAPK/ERK Mek AZD6244 ATP-independent inhibitor of MEK1 
   and MEK2 
MAPK/ERK Mek E6201 inhibitor of MEK1 and MEK2 
MAPK/ERK Mek GSK1120212 inhibitor of MEK1 and MEK2 
MAPK/ERK Mek GDC0973 MEK1 inhibitor 
MAPK/ERK Mek MEK162 inhibitor of MEK1 and MEK2 
  (binimetinib) 
                                                                        
    MAPK/ERK          Mek          D0325901 inhibitor of MEK1 and MEK2                         40 
 
 
 
   Table 1.2- Most common inhibitors being tested (clinical trials) for the treatment of melanoma. 
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6. Resistance to melanoma treatment 
 
Tumour cells typically adapt to be dependent on their specific driving oncogene and the 
pathways it regulates; this is termed oncogene/pathway addiction. This process is present in the 
majority of tumours that develop resistance to inhibitors. As the most mutant melanoma cells are 
V600EB-RAF, these tumours are common addicted to ERK1/2 signalling. 
 
 
Figure 1.6–Mechanisms of intrinsic resistance, developed by melanomas that carry 
BRAFV600E mutation due to exposure to B-Raf inhibitors47: 
1- Activation of molecular pathway by Ras activation or mutation; 2, 3- activation of 
receptor tyrosine kinases (PDGFRβ and IGF-1R) leads to RAF dimerization and 
consequent activation of downstream targets. Activation of RTKs also results in 
activation of other survival pathways, in an MEK-independent way; 4- COT is a kinase 
that can activate MEK and resist RAF inhibition. 
 
The first approach consisted in creating small molecules to target this pathway 
(BRAF and MEK inhibitors). Although BRAF and MEK inhibitors have proven clinical 
benefits in melanoma, most patients develop resistance when submitted to 
monotherapy. This is an important issue for any targeted therapy and it is crucial to find 
out the mechanisms of resistance to develop an effective therapeutic strategy for their 
reversal. In melanoma, response to B.RAF inhibitors are not durable and resistance to 
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treatment develops in 6-8 months from the initiation of therapy. Resistance is very 
common, leading to insensitivity of the RAF kinase to the inhibitor. 
Two principal mechanisms are suggested: intrinsic and acquired resistance. Some 
tumours after exposure to AZD6244, show intrinsic resistance resulting in the activation 
of the PKB pathway. It is achieved through 4 different mechanisms: activation of RAS 
due to RAS mutations; activation of receptors RTKs (PDGFRβ and IGF-1R) leads to 
dimerization of RAF compromising the suppression of ERK signalling and promote 
different/independent survival pathways. As an example, IGF-R Mediates PI3K 
Signalling in BRAF-Inhibitor Resistant Cells 45; the last mechanism is the activation of 
another MEK kinase (COT) (Fig. 1.6). Combination with MEK inhibitors appears to be 
more effective than single agent treatment. 
The acquired resistance is basically composed of two different concepts. The first 
involves the emergence of mutations in the targeted kinase that abrogate drug binding, 
such as the “gatekeeper” mutations, it usually makes the kinase constitutive activated. 
Gatekeeper mutations in the ATP-binding domain often result in increased kinase 
activity. The second one involves a “kinase switch” in which separate oncoproteins are 
up-regulated (amplification of a gene, for example) to substitute the driving oncoprotein, 
re-activating the pathway43,45 
Although promising findings suggest that simultaneous MEK and IGF-1R/PI3K 
inhibition leads to cytotoxicity in melanomas resistant to BRAF inhibitors, some tumours 
create mechanisms of evasion.22,45–48This is very surprising, since MEK1/2 mutations 
are extremely rare in cancer and do not consistently increase MEK1/2 activity. So, a 
question emerges: if acquired resistance to MEK inhibitors arises, how does it happen? 
It is a result of intrinsic and acquired resistance: loss of PTEN tumour suppressor 
protein, and increased levels of AKT signalling; gene amplification or overexpression of 
cyclin D1; promoting activation of RAS by silencing NF1; protein kinase D3 is activated 
leading to PI3K/AKT pathway activation. This way, tumour cell proliferation becomes 
independent or less dependent on activation of the BRAF-MEK-ERK pathway.49 
(Fig.1.7) 
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7.  Crosstalking 
To restore the intracellular balance, it is considered a more appropriate approach, 
targeting an entire signalling pathway, as well as the networks in which several proteins 
from distinct cascades interact which other in a phenomenon called cross talking, rather  
 
7. Crosstalking 
 
To restore the intracellular balance, it is considered a more appropriate approach, 
targeting an entire signalling pathway, as well as the networks in which several proteins 
from distinct cascades interact which other in a phenomenon called cross talking, rather 
than a single protein. 
In order to understand what mechanisms are behind the resistance in treated 
tumours and in the parallel activation of different pathways, several studies were 
performed and reported the existence of cross talking between different proteins, making 
part of large genetic networks.11(Fig.1.8) 
 
 
 
 
Figure 1.7-Mechanisms of resistance to RAF/MEK inhibitors.49  
In the presence of BRAF inhibition different pathways are triggered loss of PTEN, a 
tumour suppressor protein, increases basal levels of AKT that promotes survival. 
Gene amplification or overexpression of cyclin D1, stimulates the RB pathway. 
Silencing of the NF1 gene promotes RAS activation and regulates the senescence 
process and control of cell proliferation. Increased activity of protein kinase D3 
(PRKD3) induces activation of the PI3K-AKT signalling;  
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Figure 1.8-Model that summarizes the different genetic networks that result from the 
cross talking in melanoma13. 
The PI3K/AKT/mTOR and the MAPK pathways are the two most important and 
mutated genetic networks in melanoma. Cross talking between these two pathways 
usually occurs. 
 
In most cancers two or more pathways must be activated simultaneously to 
maintain a positive feedback loop that promotes resistance. For instance, a study revealed 
that BRAFV600E (V600E mutation results in an amino acid substitution at position 
600 in BRAF, from a valine (V) to a glutamic acid (E)), combined with PTEN tumour 
suppressor gene silencing resulted in development of melanoma with 100% penetrance, 
with metastases observed in lymph nodes and lungs41. Another study reveals that 
activated ERK increases the level of c-Jun expression by affecting its transcription and 
stability in human melanoma.24. Melanoma cells are also capable of bypassing the 
negative crosstalk from p38 to ERK that exists in other cancer cells and promote 
malignancy.42 
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8. Hypothesis 
 
Recent data within our group revealed that TRIB2 is an oncogene and novel 
biomarker for melanoma. Furthermore, our group has demonstrated that TRIB2 confers 
resistance to a range of PI3K inhibitors as well as to another anti-cancer therapeutics. 
Based on our results regarding TRIB2-resistance to PI3K inhibitors, we 
hypothesised if TRIB2 conferred resistance to inhibitors that target mTOR, and 
considering that MEK signals the alternate arm of this network and a putatively 
identified MEK 1 binding domain within TRIB2 has been identified, we hypothesized, 
that TRIB2 could confer resistance to MEK inhibitor exposure as well as bind MEK. 
Our previous results demonstrate that TRIB2 confers resistance to PI3K, so we 
also hypothesized if TRIB2 confers resistance to mTOR, another member of PI3K 
pathway (Fig.1.9). 
 
 
 
Figure 1.9-Hypothesis model in which TRIB2 confers resistance to mTOR/MEK 
inhibitors. 
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CHAPTER 2. METHODS 
 
1. Cell culture and Tissue samples 
 
1.1 Cell Culture 
 
Cell culture is one of the major tools used in cellular and molecular biology, 
providing excellent model systems for studying the normal physiology, behaviour and 
biochemistry of cells. In this project we used cell culture to reproduce in vitro the effects 
of several drugs in melanoma cells. The great advantage of this approach is the 
consistency and reproducibility of results that can be obtained from using a batch of clonal 
cells. 
The artificial environment in which the cells are cultured invariably consists of a 
suitable vessel containing a substrate or medium that supplies the essential nutrients 
(amino acids, carbohydrates, vitamins, minerals), growth factors, hormones, and gases 
(O2, CO2), and regulates the physicochemical environment (pH, osmotic pressure, 
temperature). Most cells are anchorage-dependent and must be cultured while attached 
to a solid or semi-solid substrate (adherent or monolayer culture) 
Isogenic cell lines (Table 2.1) were created in order to express different levels of 
TRIB2: 293T and U2OS were transfected to overexpress Trib2 because the basal levels 
of Trib2 in these cells are low. In the other hand, SK-Mel28 and G361 were transfected 
to knockdown the Trib2 expression (RNAi technique) because these melanoma cell lines 
have a high expression of TRIB2.  
After cell seeding (cell culture hood), the cells grew in DMEM (Sigma) with 10% 
heat inactivated FCS (Sigma) supplemented with Pen/Strep (Gibco) in T-75 flasks at the 
humid CO2 incubator. 
 
 
 
 
 
 
 
 
 
 
26 
TRIB2 confers resistance to MAPK and mTOR1 inhibitors 
CHAPTER 2. METHODS 
 
 
 
 
 
 
Table 2.1-Characteristics of the isogenic cell lines created for experiments. 
 
 
1.2 Transfection  
 
Transfection is a powerful analytical tool, that introduces foreign nucleic acids (DNA or 
RNA) into cells to produce genetically modified cells. This technique allows to study the 
genes and gene products in cells (gene function, regulation and proteins). The transfection  
 
 
Cell line 
 
Amount of protein expressed (TRIB2) 
 
293T Empty(GFP) (Human Renal cancer) 
 
low 
293T TRIB2 (Human Renal cancer) high 
U2OS Empty(GFP) (Human Osteosarcoma) low 
U2OS TRIB2 (Human Osteosarcoma) high 
G361 scramble(sc.) sh RNA (Human melanoma) high 
G361 TRIB2 sh RNA (Human melanoma) low 
SK-ML28 scramble(sc.) sh RNA (Human melanoma) high 
SK-ML28 TRIB2 sh RNA (Human melanoma) low 
 
Figure 2.1-Chemical tranfection method.59  
In this mechanism, DNA/siRNA is wrapped in the transfection reagent and delivered 
into the cell via endocytosis. 
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methods are broadly classified into three groups; biological (transduction or virus-
mediated), chemical (cationic lipids, cationic polymers, calcium phosphate), and physical 
(direct injection, electroporation, laser irradiation, magnetic nanoparticles). These 
methods have advanced to make it possible to deliver nucleic acids to specific subcellular 
regions of cells by use of a precisely controlled laser-microscope system. However, each 
method has its own advantages and disadvantages so the optimum method depends on 
experimental design and objective, and new approaches for transfection methodologies 
along with improvements to existing protocols have emerged to deliver DNA or RNA 
into cells, over the last two decades.  
One pitfall of numerous cationic lipid carriers that have been developed, is that cationic 
lipids destabilize the cell membrane, making the process toxic. 
In this project we used a new transfection reagent, jetPRIME, that is extremely 
efficient and contains very low cytotoxicity. It combines the strong interaction with the 
nucleic acid cargo from lipids, with a natural cell entry pathway (endocytosis) followed 
by efficient proton sponge-mediated endosome escape (Figure 2.1). As a consequence of 
tight cargo binding, it can be used equally well for delivery of large plasmids or small 
siRNA and their mixtures.  
The cells were transfected following the JetPrime transfection Protocol (figure 2.2). For 
optimal DNA transfection conditions, cells were used when 60 to 80% confluent, 
because few cells grow poorly, they need cell contact. On the other hand, too many 
cells result in DNA uptake resistance, as well as other essential macromolecules. The 
number of passages were always low than 20: cells may not respond to the same 
transfection conditions. 
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 The first step was to dilute 2 µg of DNA into 200 µl jetPRIME buffer and then 
vortex. After that, it was added 4 µl of jetPRIME to the mix and it was vortexed for 10s 
following a short spin. The mix was incubated for 10 minutes at room temperature and 
then it was added 200 µl of transfection mix (drop wise) per plate of cell culture. Finally, 
the plates were gently shocked and placed into the incubator for 24 hours. 
 
1.2.1. RNAi technique 
 
RNA interference, most known as RNAi, involving small interfering RNAs 
(siRNAs) and microRNAs (miRNAs) are noncoding RNAs (20- to 30-nucleotides). 
Studies started first in plants, flies, worms and RNAi has been discovered as an accidental 
observation. RNAi pathways confer a qualitative change in the way cellular networks are 
managed, and their associated proteins control and regulate gene expression in many 
ways: cell growth, tissue differentiation, heterochromatin formation, and cell proliferation. 
Another interesting fact, is that miRNAs present in a genome appears to correlate with the 
complexity of the organism.  It is being harnessed by scientists for laboratory research and 
for the development of new therapies for disease. RNAi dysfunction is linked to 
cardiovascular disease, neurological disorders, and many types of cancer.60-62  
Figure 2.2-DNA transfection protocol. 
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In 1998 Andy Fire and Craig Mello investigated the requirements for structure and 
delivery of the interfering RNA. They showed that injections of double stranded RNA was 
more effective than single stranded RNA in generating mutant phenotypes. Only a few 
molecules of double strand RNA are required to affect the cells phenotype.  
Apart all implications of these findings in biology and medicine, Andy Fire and 
Craig Mello discovery leaded to a new paradigm in molecular biology and a technique 
emerged: RNA interference.62  
RNA interference (RNAi) has been rapidly adopted as a general method for 
inhibiting gene expression in most laboratory models and it can be used to induce gene 
silencing in a diverse range of organisms including fungi, protozoans and metazoan 
animals. 
In figure 2.4, it is possible to see that RNAi does not interact with the DNA of an 
individual rather it interferes with the translation process of gene expression. The 
mechanism in which RNA is delivered to the cell is quite complex, dsRNA introduced 
into a cell is cleaved by the ribonuclease RNase III family member, Dicer, into 21 
nucleotide fragments with 5’ phosphorylated ends and 2 nucleotides unpaired and 
unphosphorylated 3’ ends. These small interfering RNAs (siRNAs) are subsequently 
incorporated into a protein.60 
 
Figure 2.3-RNAi mechanism.60  
The gene silencing by RNA interference (RNAi) is a post-transcriptional process 
triggered by the introduction of double-stranded RNA (dsRNA) into the cell. 
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complex, the RNA-induced silencing complex (RISC), where they guide the cleavage of 
homologous messenger RNAs (mRNAs), so preventing their expression (figure 2.3). 
2. Drug Time Courses 
 
These assays are essential for evaluating compound effects on cells. Traditionally 
these assays are performed at a specified endpoint after the chosen exposure time. In this 
study, we monitored compound effects on cell health at various time points during 
exposure to different drugs (table 2.2) for 12, 24, 48, 72 hours; 1, 6, 12 hours; 48hours 
or 72 hours depending on the experiment. The cell lines used for drug treatment are 
represented in table 2.1. After cell culture, cells were observed in the microscope and 
counted. After the drug treatment, we analysed the protein levels, gene expression or 
RNA transcripts by some techniques described below 
 
Table 2.2-Chemotherapeutic drugs used in time couses. 
 
 
Compounds                Target                                                                   IC50 
 
 
TORIN1                         mTORC1/2 inhibitor                                2 nM/10 nM 
BEZ235               dual ATP-competitive PI3K         4 nM /5 nM /7 nM /75 nM /6 nM 
                                      and mTOR inhibitor 
Rapamicyn                           mTOR inhibitor                                        0,1nM 
BAY766                         inhibitor of MEK 1/2                             33nM/762 nM   
 
3. RNA/Protein extraction and FACS (Fluorescence- activated cell 
sorting) samples 
 
To extract the total protein from each cell line, the cells were trypsinized, 
resuspended with medium, washed with PBS and collected for falcons. Then, the falcons 
were spun at 1100 rpm for 5 minutes at 4ºC. After that, we removed supernatant and: 
 
3.1. RNA 
 
We ressuspended with 500 μL of Trizol reagent in eppendorfs and then stored at -80ºC. 
31 
TRIB2 confers resistance to MAPK and mTOR1 inhibitors 
CHAPTER 2. METHODS 
 
 
 
 
3.2. Protein 
 
We ressuspended with 200 μL of lysis buffer (RIPA) in eppendorfs and incubated 
30 minutes on ice. After that spun at 1500 rpm for 15 minutes at 5ºC. Then, removed 
supernadant to new eppendorfs and stored at -80ºC. 
To determine the protein concentrations (protein quantification) in each sample 
we used the Quick Strat™ Bradford Protein Assay (BioRad) and the NanoDrop 2000 
UV-Vis Spectrophotometer (ThermoScientific) following the manufacturers guidelines. 
 
3.2.1. Protein Quantification/Bradford Assay 
 
In our project, some experiments often required a sensitive method for protein 
quantification. The Bradford Assay is a dye-binding assay in which a differential color 
change of a dye occurs in response to various concentrations of protein: It involves the 
addition of an acidic dye Coomassie ® Brilliant Blue that binds to the proteins present in 
the solution. The absorbance ranges from a maximum of 465 nm to 595 nm. The 
Coomassie blue dye binds to primarily basic and aromatic amino acid residues, especially  
 
 
 
 
 
Figure 2.4- Lambert-Beer´s Law. The Beer´s law is written in the format: y=mx+b, so 
it is possible to construct a graphic in which concentration is the independent variable 
and absorvance is the dependent variable. The parts of the equation are: A=absorbance, 
Ɛ=molar absorptivity (constant for a given solute at a given wavelength, C=molar 
concentration (mol/L)) 
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arginine. Beer’s law may be applied for accurate quantitation of protein by selecting an 
appropriate 63ratio of dye volume to sample concentration (figure 2.4). Then, it is possible 
to create a calibration graph, and use it to measure the concentration of an unknown 
solution (protein concentration). 
It was Determined the best fit of the data to a straight line in the form of the 
equation "y = mx + b" where y = absorbance at 595 nm and x = protein concentration, we 
used this equation to calculate the concentration of the protein sample based on the 
measured absorbance. A dilution of the protein sample may be required for the resulting 
absorbance to fall within the linear range of the assay. Every time the absorbance of the 
test sample was outside of the absorbance range for the standards, then the assay was 
repeated with a more appropriate dilution.  Samples incubate at room temperature for 10-
30 minutes. Then, 99 µl (blank microtube 100 µl) of Bradford reagent was added to each 
microtube, and let stand 5 minutes at room temperature. We displayed 10 µl of dH2O 
drops in a parafilm plate and diluted 1 µl of each sample. 1 µl of this dilution was added to 
the microtubes with Bradford reagent. The last step of this procedure was to measure the 
absorbance of each sample at 595 nm using a NanoDrop 2000 UV-Vis Spectrophotometer 
(ThermoScientific). The data was analysed with Microsoft Office Exccell 2010 ™ 
 
3.3. FACS (Fluorescence-activated cell sorting) 
 
FACS is a method used to detect cells that have lost some of their DNA in late 
stage of apoptosis process following endonucleases activity. Endonucleases degrade 
DNA in small fragments of about 180 bp, which accumulate in the cell. After ethanol 
fixation and wash with a phosphatecitrate buffer, these DNA oligimeres leak out of the 
cell decreasing the DNA content. Using the nucleic acid stain propidium iodide (PI), the 
number of hypodiploid cells undergoing this process can be counted in subG1 region of 
PI histogram. 
To fix cells, we ressuspended with 500 μL of 70% ethanol in eppendorfs and 
stored at 4ºC on the fridge at least 24 hours. 
Samples were run on FACS after propidium iodide (2.5 mg mL-1) was added to 
the fixed cells. 10,000 gated, total events were scored per study from triplicate studies.   
Data was analysed using FACS-express 3 (De Novo software) 
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4. Western Blotting 
 
Western blotting (also called immunoblotting because an antibody is used to 
specifically detect its antigen) was introduced by Towbin, et al. in 1979. It is now 
a routine technique for protein analysis.  This is an analytical technique used to 
identify specific proteins using an electrophoresis gel to separate proteins by their 
density.  
The first step in a western blot is to prepare the protein sample by mixing it with a 
blue solution to stain proteins (loading buffer) that contains a detergent called sodium 
dodecyl sulfate (SDS), which makes the proteins unfold into linear chains and coats then 
with a negative charge. Another important component of loading buffer is β-
mercaptoethanol that denature proteins. Next, the protein molecules are separated 
according to their sizes using a method called gel electrophoresis (figure2.5).  
 
 
Following separation, the proteins are transferred from the gel onto a blotting 
membrane. There are several techniques to transfer the proteins to the membranes 
(nitrocellulose or PVDF). In this project we used the semi-dry transfer system Trans-
Blot® SD Semi-Dry Transfer Cell (Bio-Rad) (figure 2.6). 
 
Figure 2.5-Western blot electrophoresis. After cell lysis, loading buffer is added to 
supernatant, heated at 95ºC and loaded into the gel wells. Proteins present in solution are 
separated according to their weight, migrate to the positive pole after running in a two 
phase agararose gel (stacking gel + resolving gel). 
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Figure 2.6-Western blot semi-dry transfer apparatus. 
 
Once the transfer is complete, the membrane carries all of the protein bands 
originally on the gel. Next, the membrane goes through a treatment called blocking, 
which prevents any nonspecific reactions from occurring. The most common block 
reagents are BSA and milk that contain caseins (non-immunoresponsive proteins) 
(figure 2.7). 
 
 
Figure 2.7-Western Blot Blocking and incubation.  
After incubation in block solution (milk or BSA), the membrane is incubated with the 1º 
antibody and 2º antibody, respectively 
The membrane is incubated with an antibody called the primary antibody, which 
specifically binds to the protein of interest. Following incubation, any unbound primary 
antibody is washed away, and the membrane is incubated yet again, but this time with a 
secondary antibody that specifically recognizes and binds to the primary antibody. The 
secondary antibody is linked to a reporter enzyme that produces color or light, which 
35 
TRIB2 confers resistance to MAPK and mTOR1 inhibitors 
CHAPTER 2. METHODS 
 
 
 
 
allows it to be easily detected and imaged. For detection we used eenhanced 
chemiluminescence (ECL), a method which provides highly precise detection of proteins 
from Western blots. It consists of a chemiluminescence reaction: horseradish peroxidase 
catalyzes the oxidation of luminol into a reagent which emits light when it decays. Since 
the oxidation of luminol is catalyzed by horseradish peroxidase (HRP), and it is 
complexed with the protein of interest on the membrane, the amount and location of light 
that HRP catalyzes the emission of, is directly correlated with the location and amount of 
protein on the membrane. These steps permit a specific protein to be detected from among 
a mixture of proteins.64 
After protein quantification, our extracted proteins samples were diluted in to 2x 
lammeli loading buffer and heat at 95ºC for 5 minutes in a thermal block. Then samples 
were loaded into our 5% SDS-PAGE gels, prepared accordingly with table 2.3. In this gel, 
proteins are concentrated in gel wells and ready to migrate into the second gel. In second 
gel, 10% SDS-PAGE (table 2.4) proteins coated with negative charges will migrate to the 
positive pole After that, separated proteins from the gel were transferred to  
 
Table 2.3-Solutions f o r  Stacking g e l s  f o r  tris-glycimide S D S -polycrimide 
G e l  electrophoresis. 
 
 
5% gel                    Volume=4ml 
 
 
H2O                                 2,7ml 
1,5M Tris (ph=6,8)                     0,5ml 
10% SDS                            0,04ml 
10% ammonium sulfate   
(APS)                             0,04ml 
30% acrylamide         0,67ml                     
     TEMED                             0,004ml 
 
 
nitrocellulose membranes (Amersham) previously wet with transfer buffer. In this process 
a Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad) was used for 60 minutes. Then, the 
membrane was blocked in 5% milk (in wash solution that contains PBS  
 
36 
TRIB2 confers resistance to MAPK and mTOR1 inhibitors 
CHAPTER 2. METHODS 
 
 
 
 
Table 2.4-Solutions for resolving gels for Tris-glycimide SDS- polycrimide SDS- 
polycrimide gel electrophoresis. 
 
 
10% gel                    Volume=10ml 
 
 
H2O                                      4,0ml 
1,5M Tris (ph=8,8)                       2,5ml 
   10% SDS                                   0,1ml 
10% ammonium sulfate 
    (APS)                                  0,1ml                           
30% acrylamide                            3,3ml                         
       TEMED                             0,004ml 
 
 
and Tween20) for 1 hour (preventing non-specific antibody binding). After blocking, 
membranes were immunoblotted with primary antibodies (dilution 1:1000) overnight at 
4ºC in a platform shaker. The primary antibodies are specified in Table 2.5. 
 
 
Table 2.5-Primary antibodies 
 
 
                 Primary antibodies                                  Information 
 
        
Total MEK                                Sc-436; Rabbit; Santa Cruz Biotechnology 
       Total-ERK                             Sc-94; Rabbit; Santa Cruz Biotechnology 
          P-ERK                               Sc-7383; Mouse; Santa Cruz Biotechnology 
          TRIB2                                   Sc-292013; Rabbit; Santa Cruz Biotechnology 
          TRIB2                                                             Homemade 
           Actin                                   I-19; sc-1616; Goat; Santa Cruz Biotechnology 
         Total AKT                           C-20; sc-1618; Goat; Santa Cruz Biotechnology 
           p-AKT                         SSer 473; sc-7985; Rabbit; Santa Cruz Biotechnology 
Total FOXO (FKHRL1)                  N-16; sc-9813; Goat; Santa Cruz Biotechnology  
    FOXO (p-FKHRL1)           p-Ser253; sc-101683; Rabbit; Santa Cruz Biotechnology 
            Fas-L                              C-178; sc-6237; Rabbit; Santa Cruz Biotechnology 
            BIM                                  H-191; sc-11425; Rabbit; Santa Cruz Biotechnology 
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Table 2.6-Secondary antibodies 
 
Secondary Antibodies   Information 
 
Anti-rabbit                IgG-HRP; sc-2004; 
Goat; Santa Cruz 
Biotechnology 
Anti-mouse               IgG-HRP; sc-2020; 
Donkey; Santa Cruz 
Biotechnology 
Anti-goat                 IgG-HRP; sc-2314; 
Donkey; Santa Cruz 
Biotechnology 
 
 
After incubation, we washed the membranes 3 times, 10 minutes each one with 
wash solution (Tris-buffered saline with 0,1% Tween 20 buffer (TBST). Then, we 
prepared the secondary antibodies (Table 2.6) with block solution (1:1000) and let the 
membrane incubate 1hour in a platform shaker. We made 3 washes again with wash 
solution, 10 minutes each one. Finally, we prepared ECL solution (solution I- Luminol 
Reagent + solution II- Oxidizing Reagent) and we put the membrane in the ECL solution 
over 5 minutes and watched the images using a Molecular Imager® ChemiDoc™ XRS 
System (BioRad). 
 
5. Co-Imunnoprecipitation (Co-IP) 
 
Co-Imunnoprecipitation is a technique to identify protein-protein interactions by 
using protein-specific antibodies to capture proteins that are bound to a specific target 
protein. The cells were washed with medium and added trypsin to the plates with 
cultivated cells so the cells remove from the bottom of plates. The solution was collected 
to new eppendorfs and centrifuged, and the supernatant was collected to new tubes. The 
protein A/G agarose beads (Sigma) were washed 2 times with PBS and a 50% protein 
A/G working solution in PBS was made. Each indicated antibody was added to the beads 
for 1 hour, slightly agitated. After 1 hour the beads were washed (x2) with PBS. 500 µg 
of total protein lysate was added to each set of beads and incubated overnight at 4ºC. 
Samples were centrifuged (max speed), the pellet was kept, and washed with pre- chilled 
PBS (x3). SDS loading buffer was added to beads and the samples heated to 
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95ºC for 5 minutes. Samples were extracted and run on an appropriate percentage SDS- 
gel. 
 
6. Chromatin Imunnoprecipitation (ChIP) 
 
Chromatin Immunoprecipitation is a technique used to study the interaction 
between proteins and DNA in the cell: it is possible to see how transcription factors 
regulate gene transcription.  
 
The plates were washed with medium, and a 1% formaldehyde/PBS solution was 
added to cross-link proteins to DNA. The solution was removed, and the plates were 
washed with ice cold PBS (x3). Cells were scraped f rom the plates with 1M Tris-HCl 
with 10mM DTT, and transferred to Eppendorf tubes. After centrifugation, the 
Figure 2.8-Chromatin. Immunoprecipitation Workflow 
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pellets were washed with Buffer I (10 mM Hepes, pH 6.5; 0.25% Triton X-100; 10 mM  
EDTA, pH 8.0; 0.5 mM EGTA, pH 8.0) and buffer II (10 mM Hepes, pH 6.5; 200 mM 
NaCl; 10 mM EDTA, pH 8.0; 0.5 mM EGTA, pH 8.0). After centrifugation, the pellet was 
resuspended in lysis buffer (made fresh with protease inhibitors (PI) 50 mM Tris, pH 8.1, 
1% SDS; 10 mM EDTA, pH 8.0; proteaseinhibitors(1X)). The cells were sonicated (6 
times for 10 seconds each sample) on ice, to shear DNA to an average fragment size of 
200-500 base pairs. After centrifugation (at max speed for 15 minutes), the supernatant 
was transferred into a new eppendorf. 300 μl of Buffer D20 mM Tris, pH 8.11%Triton 
X-100, 2 mMEDTA, pH 8.0, 150 mM NaCl, protease inhibitors (1X). 100 μl input 
samples were removed at this stage. The input samples were heated overnight at 65°C. 
To the remaining sample (after the inputs were removed), we added sheared salmon 
sperm DNA, the antibody of interest and protein G-fast flow beads (Sigma) and Buffer 
D. After incubation overnight at 4ºC, the beads were pulled down and washed with TSE I 
(20 mM Tris, pH 8.1, 150 mM NaCl, 1% Triton X-100, 2 mM  EDTA, pH 8.0, 0.1%SDS), 
TSE II 20 (mM Tris, pH 8.1 500 mM NaCl 1% Triton X-100 2 mM EDTA, pH 8.0, 
0.1%SDS) and TSE III10 mM Tris, pH 8.1, 0.25M LiCl, 1% NP-40, 1% Deoxycholate, 1 
mM EDTA, pH 8.0) . Afterwards the beads were washed with ice cold TE. The DNA 
was extracted with three washes with a solution of NaCHO3 and SDS. Once extracted 
the samples were transferred to a fresh Eppendorf and heated overnight at 65ºC. Our input 
and the ChIP samples were loaded into Sigma-PCR clean-up columns and after 
washing our  immunoprecip i ta ted  DNA eluted with 30 μl dH2O. Samples were 
stored at -20ºC. 
 
7. cDNA synthesis 
 
The central dogma of biology states that biological information is transmitted from 
DNA to RNA to protein. Yet in some situations biological information can be converted 
from RNA to DNA. Some viruses that have RNA genome are able to convert their RNA 
genome into DNA thru a polymerase enzyme (reverse transcriptase). This discovery 
enabled the opportunity of converting mRNA into complementary DNA (or cDNA). 
Using this enzyme together with a few other components (dNTPs and primers), we are 
able to reproduce this mechanism in biological research. 
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For the cDNA synthesis, NZY First-Strand cDNA Synthesis Kit (nzytech) was 
used. Each sample was prepared in a microcentrifuge tube with the amounts of reaction 
components present in Table 2.7 
. 
Table 2.7–Reagents necessary to cDNA synthesis. 
 
 
NZY Master Mix preparation 
 
 
NZYRT 2x Master Mix                         10μl 
NZYRT Enzyme Mix                            2μl 
RNA samples                                  5μl 
DEPC-treated H2O                              3μl 
 
 
 
 The solutions were then gently mixed and inserted in C1000 Thermal Cycler 
(BioRad) with the following steps: incubation at 25ºC for 10mins; Incubation at 50ºC for 
30mins; Reaction inactivation by 85ºC heating for 5mins. The samples were then put on 
ice and 1μl NZY RNAse H (E.coli) was added. A last incubation at 37ºC was done for 
20mins. The cDNA product was afterwards used in PCR and further stored at -20ºC until 
required. 
 
 
 
Figure 2.9- cDNA synthesis Workflow.65 
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8. Real Time Polymerase Chain Reaction (qRT-PCR) 
 
Polymerase Chain Reaction (PCR) is a DNA amplification technique and 
considerate to be a cornerstone in modern molecular biology. Since DNA is commonly 
difficult to analyse in cellular concentrations, this technique allows us to acquire DNA 
amounts high enough to be detectable in signal quantification. The technique is centred 
in a specific DNA reproduction thru a polymerase enzyme that is controlled by 
temperature changes: the method begins with the temperature being raised to 95ºC so the 
double stranded DNA detaches into single strands (denaturation); the temperature is then 
lowered to 60ºC, allowing primers to bind to the selective DNA sites (annealing); since 
the polymerase enzyme has now sites to bind to, temperature is raised to the polymerases 
optimal working temperature (around 72ºC) and replication takes place (extension). 
These steps are repeated about 40 times (cycles) and in each cycle the amount of DNA is 
duplicated. 
RT-PCR is founded on the same principle, yet instead of analysing the DNA 
amplification in an agarose gel, the process is monitored by fluorescence the growing in 
a real-time PCR machine. 
 
Table 2.8-RT-PCR reagents 
 
 
            Reagent                                  Volume (µl) 
 
 
2xluminolCt SYBR Green qPCR                                      10 
Ready Mix 
25µM Forward Primer                                                       1 
25µM Reverse Primer                                                        1 
DNA                                                                                   2 
1x internal reference dye                                                    1 
dH2O                                                                                  5 
Final Volume                                                                      20 
  
 
 
 
The procedure was based on RT-PCR protocol (sigma): after the reagents and 
samples were added to a plate well according to Table 2.8, they were put in the RT-PCR 
machine (CFX96TM Real Time System – BioRad). 
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8.1 DNA electrophoresis 
 
DNA gel electrophoresis has the same background as the Westernblot gel 
electrophoresis, yet for DNA instead of proteins: In this method, negatively charged 
molecules (as DNA and proteins) are able to migrate thru a pored gel from the negative 
pole (cathode) to the positive pole (anode) of the electrophorator. Since the small weight 
molecules migrate faster than the larger ones there will be a sized separation of the all 
fragments. The results can then be visualized using UV light that illuminates a previously 
added fluorescent dye (for instance SYBR Green or ethidium bromide). 
In this procedure a 1% agarose gel with two comb lines was used. After 
assembling the support, the gel was prepared: 2gr of agarose were added to 200ml 1x 
TAE and mixed. The mixture was melted in the microwave during 30 seconds pulses on 
maximum power and further mixed until all agarose was dissolved. 1μl of Green safe 
(nzyTech) was added to the agarose buffer before shedding it into the support. 
Afterwards, the combs were placed in their rightful position. After the gels 
polymerization, it was placed in the gel box and filled with 1x TAE. For each sample, 1 
μl DNA loading buffer was placed on Parafilm for further dilution with 10μl of the sample 
solution. 10 μl of this dilution were then placed in the wells, together with one well of 
loading marker. The gel was run at 100v during 30mins and the results were observed 
using Molecular Imager ChemiDocTM XRS System (BioRad) 
 
9. Dual staining Microscopy 
 
Cell staining is a technique that can be used to better visualize cells and cell 
components under a microscope. By using different stains, one can preferentially stain 
certain cell components, such as a nucleus or a cell wall, or the entire cell. Most stains can 
be used on fixed, or non-living cells, while only some can be used on living cells; some 
stains can be used on either living or non-living cells. 
Cell staining techniques and preparation depend on the type of stain and analysis 
used. One or more of the following procedures may be required to prepare a sample: 
Permeabilization- treatment of cells, generally with a mild surfactant, which dissolves 
cell membranes in order to allow larger dye molecules to enter inside the cell. Fixation - 
serves to "fix" or preserve cell or tissue morphology through the preparation process. 
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This process may involve several steps, but most fixation procedures involve adding a 
chemical fixative that creates chemical bonds between proteins to increase their rigidity. 
Common fixatives include formaldehyde, ethanol, methanol, and/or picric acid. 
Mounting - involves attaching samples to a glass microscope slide for observation and 
analysis. Cells may either be grown directly to the slide or loose cells can be applied to a 
slide using a sterile technique. Thin sections (slices) of material such as tissue may also 
be applied to a microscope slide for observation. Staining application of stain to a sample 
to color cells, tissues, components, or metabolic processes. This process may involve 
immersing the sample (before or after fixation or mounting) in a dye solution and then 
rinsing and observing the sample under a microscope. Some dyes require the use of a 
mordant, which is a chemical compound that reacts with the stain to form an insoluble, 
colored precipitate. The stainning will remain on/in the sample when excess dye solution 
is washed away. 
Slides containing each sample, disposed face up, were observed in the 
Microscope to check cell confluence. If they are all ok, we can now proceed with 
the dual staining protocol. Each sample was put in a 6 well-plate (35mm), one lamella 
for each well with PBS solution. They were washed with 1x PBS and block solution was 
prepared (1:30). Drop equal amounts (+/- 200ul) of blocking solution in the glass with 
the parafilm paper for each lamella. Slides were incubated 37ºC, 30mins. Lamellas were 
removed from the Humified Chamber and turned face up in the six plate wells and 
washed with PBS (1x) three times. The remaining block solution were removed from the 
glass with parafilm. Primary antibody was added in a 1:500 concentration (in PBS) and 
left in a humidified chamber for 1h at 37ºC. The samples were washed three times with 
PBS and the secondary antibody was added for 30mins (also at 37ºC in a humidified 
chamber) and with a 1:1000 concentration. Again the samples were washed three times 
with PBS. The slides were prepared according to Invitrogen Clean MountTM Mounting 
solution protocol. To avoid bubbles, bubbles were removed from the tip of pipette, the 
surface of the non-sample side of the coverslip was cleaned prior to imaging, in order to 
remove fingerprints, residual salts, and other contaminants that can diminish image 
quality. A small amount of mounting medium was applied to the surface of the slide. The 
coverslip containing the sample was removed from the buffer, blotted the excess of buffer 
and slowly we tip the coverslip onto the mounting medium. The slides were then 
incubated at 60ºC for 30 minutes. 
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CHAPTER 3. RESULTS 
 
1. TRIB2 confers resistance to mTOR1 complex inhibition 
 
Previous data from our Laboratory shows that TRIB2 confers resistance to 
BEZ235, a potent PI3K/mTOR inhibitor. Based on this data, we wanted to address if 
TRIB2 could confer resistance to specific targeted therapeutics within this large 
signalling cascade. We hypothesised that TRIB2 is also conferring resistance to 
inhibition of the mTORC complex, another component of the PI3K/AKT pathway.  
To investigate how TRIB2 expression confers resistance to mTOR1 inhibition, 
we used isogenic cell lines with matched TRIB2 protein expression (high/low levels). 
Isogenic lines were treated with rapamycin a potent inhibitor of mTORC1 in a drug 
time course. 
We noticed that 72 hours post treatment, some significant changes occur, based 
on the concentration of TRIB2 within the cells. In order to be seen in the SubG1 area, 
in FACS output, a cell must have lost enough DNA to appear there. This means that, if 
cells enter apoptosis from the S or G2/M phase of the cell cycle or if there is an  
 
 
 
 
Figure 3.1- TRIB2 status confers resistance to rapamycin. 
Different isogenic cell lines U2OS, G361 and SK-MeL28 were treated with 1 nM 
rapamycin and 72 hours post exposure. SubG1 population was determined by FACS 
analysis (PI staining). N=6, 50,000 total events counted per samples. Stats are two-
tailed ANOVA and P values are shown above each analysis bracket. U2OS-Empty 
(black bar), G361-TRIB2shRNA and SK-MEL28-TRIB2shRNA (white bars) represent 
the cells that contain low levels of TRIB2. U2OS-TRIB2 (white bar), G361-sc.shRNA 
and SK-MEL28-sc.shRNA (black bars) represent the cells that contain high levels of 
TRIB2. 
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aneuploid population undergoing apoptosis, they may not appear in the SubG1 peak. 
The remaining cells that have lost DNA for any other reason, will appear in the SubG1 
region. It is possible to see that the U2OS-TRIB2 (high expression of TRIB2) cell line 
has a significantly lower percentage of Sub-G1 cells compared with U2OS-Empty cells 
(low expression of TRIB2) (Fig. 3.2). G361-TRIB2shRNA and SK-MEL28-
TRIB2shRNA (that have low levels of TRIB2) show the opposite pattern. This data 
suggests that the presence of TRIB2 negatively correlates with the number of SubG1 
cells (dead cells), and subsequently the cells resist treatment. This means that, when 
TRIB2 is present, we have more viable cells, while rapamycin treatment is performed. 
 
2. TRIB2 does not confer resistance to mTORC2 complex inhibition. 
 
To test the hypothesis that TRIB2 is conferring resistance to mTORC2 
inhibition, we submitted isogenic cell lines to a time course up to 72 hours with 
TORIN1 and performed FACS analysis as described in methods section. Surprisingly, 
we noted that the treatment profiles were completely different compared to rapamycin 
treatment (Fig. 3.2). We expected that TRIB2 could confer resistance to mTORC2 
inhibition, but this is not the case: the over expression of TRIB2 produces no effect on 
cells when exposed to TORIN1. The percentage of Sub-G1 cells for cell lines that 
overexpress TRIB2 (U2OS TRIB2; 293T TRIB2 and SK-MeL28 scramble) is higher 
when compared with cells with endogenous levels or shRNA knocked down TRIB2 , 
(U2OS Empty, 293T Empty and SK-MeL28 shRNA). This data suggests that TRIB2 
does not confer resistance to mTORC2 complex inhibition. 
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To validate these results, the following step was to evaluate if the inhibitors that 
we use were functional, as well as if the cell lines with TRIB2 shRNA knock down 
was effective (and that TRIB2 was indeed knocked down). We performed the protein 
expression analysis using SDS-PAGE immunoblotting, according with the protocol 
described in methods section. It is possible to see that TRIB2 is only expressed in the 
scramble sequence cell lines (Fig. 3.3). In contrast, the two different TRIB2 shRNA 
sequences were highly effective at knocking down TRIB2 (in two cell lines with high 
endogenous TRIB2 protein expression).  We can conclude that the transfection and the 
respective Knock down of TRIB2 were effective. 
 
 
 
 
Figure 3.3- The TRIB2 knock down is efficient. 
Western blot analysis of TRIB2 Knock Down efficiency. The first lane of each panel 
represents the scramble transfection of shRNA. Lanes 2 and 3 represent the constructs 
#1, #2 respectively, that result from the shRNA TRIB2 transfection. 50 µg of total 
protein lysate was loaded per lane and samples were probed for total TRIB2 and β- 
actin expression (control). 
 
 
 
Figure 3.2- TRIB2 do not promote resistance when cells are treated with mTORC2 
inhibitors. 
Isogenic cell lines treated with TORIN1 (100 nM) at 72h post treatment, the percentage 
of SubG1 cells were analysed by FACS (PI staining). 50,000 total events counted per 
samples. Stats are two -tailed ANOVA and P values are shown above each analysis 
bracket. U2OS-Empty (black bar), G361-TRIB2shRNA and SK-MEL28-TRIB2shRNA 
(white bars) represent the cells that contain low levels of TRIB2. U2OS-TRIB2 (white 
bars), G361-sc shRNA and SK-MEL28-sc.shRNA (black bars) represent the cells that 
contain high levels of TRIB2 
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Having confirmed that our cell lines had matched TRIB2 protein expression 
levels, it was also necessary to evaluate if the PI3K, mTOR1, mTOR1/2 inhibitors 
were working properly. 
 
3. Confirmation of PI3K, mTOR1 and mTOR1/2 inhibitor efficiency 
 
To examining the efficiency of the principal targets (PI3K; mTOR1 and 
mTOR1/2) inhibition, we treated cells with BEZ235 (PI3K inhibitor) and rapamycin 
(mTOR1/2 inhibitor) and confirmed protein expression for each cell line by Western 
Blot analysis. We probed for TRIB2, Total-AKT, pSer473-AKT and pThr308-AKT. It 
was expected that TRIB2 was over expressed in transfected cells (U2OS-TRIB2, 
treated and non-treated). For U2OS-GFPA TRIB2 should be less concentrated because 
the endogenous levels of TRIB2 in this type of cells is low. When we use a PI3K 
inhibitor (BEZ235), the results for TRIB2 confirm the expectations: low levels 
(endogenous) for U2OS GFP non-treated cells and high expression of TRIB2 is 
present in the remaining two cell lines, that were transfected to over express TRIB2 
(U2OS TRIB2 non-treated and U2OS TRIB2 BEZ235). We also observed that when U2OS-
GFP cells are treated with BEZ235, they are stimulated to express TRIB2.  
We had an analogous thought when this matched cell line was treated with 
rapamycin: TRIB2 should be expressed in transfected cells (U2OS-TRIB2, treated 
and non-treated), and should be less present in U2OS GFP cells (treated and non-
treated). 
The data shows that TRIB2 is overexpressed in U2OS TRIB2 (treated and non-
treated) and is low in U2OS GFP cells (treated and non-treated). To notice that 
rapamycin produces no effect in the expression of U2OS-GFP treated cells (Fig.  3.5). 
AKT is a serine/threonine protein kinase that functions as a critical regulator of 
cell survival and proliferation. It contains two regulatory phosphorylation sites: 
Threonine 308 in the activation loop within the kinase domain and Serine 473 in the C-
terminal regulatory domain, and the activation of AKT requires the phosphorylation of 
these two residues. It was expected that at least one of these two residues was activated 
when cells were treated with BEZ235 or rapamycin. 
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When we probed for total-AKT (activated and non-activated proteins) the 
results for protein expression are very similar for all lanes. When we did a more precise 
analysis to find out which residue of AKT is being phosphorylated in the presence of 
high TRIB2, we saw that pThr308-AKT is expressed equally in both experiments 
(rapamycin and BEZ235) with no significant impact. However, a very interesting result 
emerges when we look to pSer473-AKT: phosphorylated AKT at this residue is 
overexpressed when TRIB2 is expressed too, independently of the treatment (Non-
treatment; BEZ235 or rapamycin) (Fig. 3.4). 
These results strongly suggest that the resistance mediated by TRIB2 to PI3K/m 
TOR1 inhibitors requires the phosphorylation of AKT´s Serine in position 473. 
 
 
Results so far implicate resistance via PI3K and AKT. However, there is also 
resistance via mTOR1 (but not with mTOR1/2 dual inhibitors). We have seen that this 
resistance is mediated by TRIB2, which leads to the increase of pSer473-AKT. 
Another important thing that we know, is that mTORC2 plays a critical role in AKT1 
'Ser-473' phosphorylation, facilitating the activation of AKT1´s loop on 'Thr-308' by 
PDK1.This step is a prerequisite for the full activation of AKT. 
 
Figure 3.4- TRIB2 resistance occurs due to phosphorylation of Ser473 of AKT. 
Western blot analysis of PI3K signalling pathway. TRIB2 positive regulates the 
phosphorylation of Ser473 of AKT. 50 µg of total protein lysate was loaded per lane 
and samples were probed for total TRIB2, total AKT, pSer473-AKT, pThr308-AKT and 
β- actin expression. 
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These two ideas lead us to investigate what happens if we block mTORC2. One 
of the principal components of mTORC2 is Rapamycin-insensitive companion of 
mammalian target of rapamycin (RICTOR) We transfected two different cell lines 
(U2OS and 293T) to knock RICTOR down and “turn off” this complex. First, we 
performed a western blot to analyse the knock down efficiency by measuring the 
protein expression of the cells transfected. It is possible to see that RICTOR expression 
is higher in the scramble lane, compared with the #1, #2, #3 constructs (Fig. 3.5). This 
result shows that the transfection is efficient, the RICTOR expression levels are low. 
 
4. RICTOR and FOXO3a knock down increases resistance to dual 
PI3K/mTOR inhibitors 
 
From previous results in our lab, we know that the knockdown of FOXO3a, an 
important transcription factor and a downstream target of AKT, raises the cell 
viability in a TRIB2 independent manner. We performed a RNAi knock down assay, 
to knock down RICTOR, an important component of mTORC2 complex, in order to 
block AKT activation via mTOR. We expected that this resulted in the molecular shut 
down of the AKT pathway. As a consequence, cells would resist to mTOR inhibitors. 
When we analysed cell samples 72 hours post exposure to BEZ 235, we could 
observe that empty U2OS RICTOR shRNA (TRIB2 expressing cells) and TRIB2 
Figure 3.5 The RICTOR knock down is efficient. 
Western blot analysis of RICTOR Knock Down efficiency for two different cell line, 
U2OS and 293T.Scramble lane is the positive control. Lanes 2,3 and 4 correspond to 
#1, #2 and #3 constructs respectively, obtained after TRIB2-shRNA transfection. 100 µg 
of total protein lysate was loaded per lane and samples were probed for total Total- 
RICTOR and β- actin expression. 
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U2OS RICTOR shRNA (do not express TRIB2) present approximately the same 
number of sub G1 cells indicating that the number of dead cells is independent from 
the presence of TRIB2. These results show that when RICTOR expression is silenced, 
the TRIB2-mediated resistance to BEZ235 is lost. These findings are very similar with 
FOXO3a knocked down cells results. knockdown of RICTOR expression prevented 
the activation of AKT and dramatic increase cells survival (Fig. 3.6). It suggests that 
mTORC2 is crucial in the activation of AKT and sub consequently a key regulatory 
piece for the full activation of this pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. TRIB2 confers resistance to MEK inhibiton 
 
 
 
Several observations made us hypothesize that TRIB2 might be involved in 
mediating resistance to MEK inhibitors. TRIB2 has been shown to have a prominent 
role in melanoma and mediates resistance to drugs relevant in the treatment of 
melanoma. 
Fig. 3.6 TRIB2 resistance is lost, when RICTOR or FOXO3a are knocked down 
Isogenic cell lines, U2OS and 293T, were treated with 100 nM BEZ235 and 72 hours 
post exposure, SubG1 population was determined by FACS analysis (PI staining). N=6, 
50,000 total events counted per samples. Stats are two-tailed ANOVA and P values are 
shown above each analysis bracket. FOXO3a data kindly provided by Dr Richard Hill. 
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These compounds are in clinical trials and being proposed to treat metastatic 
melanoma. One of the most extensively tested agents is the MEK inhibitor BAY766 
that we used in our experiments. 
To support further this hypothesis, we performed a time drug course in which 
we treated the cells for 72 hours with BAY 766. The number of dead cells were 
analysed by FACS for three different isogenic cell lines (U2OS; G361 and SK-
MeL28). We the analysed this result and it is possible to observe that cells which 
contain increased levels of TRIB2 (U2OS TRIB2; G361 scramble shRNA and SK-
Mel28 scramble shRNA) presented a higher number of sub G1 cells, when compared 
with cells that express low levels (Fig. 3.7) 
This data suggests that the protein TRIB2 confers resistance to MEK inhibition 
treatment in different cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.7 TRIB2 is a good candidate for MEK inhibition resistance. 
Different isogenic cell lines, U2OS, G361 and SK-MeL28, were treated with 100 nM 
BAY 766 and 72 hrs post exposure, SubG1 population was determined by FACS analysis 
(PI staining). N=6, 50,000 total events counted per samples. Stats are two-tailed 
ANOVA and P values are shown above each analysis bracket. 
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5. BAY766 effectively inhibits ERK phosphorylation 
 
The next step was to find if BAY 766 was effective. For that we analysed the 
protein expression of one of the most important downstream targets of MAPK 
pathway: ERK kinase. We performed a time drug course in which we treated the cells 
for 0, 12, 24, 48 and 72 hours with BAY 766, and after probing for two different forms 
(activated and non-activated) of ERK, we analysed the protein expression by western 
blot. This compound, as a MEK inhibitor, should decrease the activation of ERK (p-
ERK), one of the molecular targets of MEK. The non-phosphorylated ERK (total-
ERK) would have no significant changes in both expressing and non-expressing cells.  
Analysing the western blot, it is possible to observe in the left panel (SK-
MeL28 TRIB2 shRNA cells) and top lane (pTyr204-ERK1) that the shTRIB2 cells 
(low levels of TRIB2) have significantly lower activated ERK at each time point. 
On the right panel, TRIB2 over expressing cells have higher pTyr204-ERK that 
gradually decreases post-BAY766 treatment (12, 24, 48, 72 hours), as expected. 
(Fig. 3.8). 
Analysis at the bottom lane that corresponds to non-active ERK (total-ERK) 
that function as a control, shows that non-treated TRIB2 expressing cells (right panel) 
have clearly higher total-ERK compared to TRIB2 shRNA cells (left panel). 
Surprisingly, it is also possible to see a decrease in total ERK at 48 and 72 hours post-
BAY766 treatment. 
Another important observation is that, generally, phosphor-ERK increases in 
cells that over express TRIB2(left and right panel). 
These results indicate that BAY 766 produces a decrease in phosphor-ERK in 
TRIB2 expressing cells. The unexpected result is that BAY766 induces alterations in 
total-ERK along time, in both cell types. 
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Figure 3.8- Increased pTyr204-ERK in high TRIB2 expressing cells. 
Western blot time course analysis for MEK/ERK signalling pathway, following 100 nM 
BAY766 treatment. 100 µg of total protein lysate was loaded per lane and samples were 
probed for total ERK, pTyr204-ERK and β- actin expression. The MAPK pathway 
activity was reflected by the level of phosphorylated ERK detected with specific anti-
phosphorylated ERK (pTyr204-ERK) antibody. Total ERK (total-ERK) was used for 
quantity control of proteins (N=1). 
 
6. Microscopy Analysis 
 
The goal of the next experiment was to evaluate the molecular consequences for 
the MAPK pathway, when we inhibit MEK. We hypothesised that expressing and non-
expressing TRIB2 cells would present significant differences in ERK phosphorylation. 
Having in mind that ERK is one of the downstream targets of MEK, it was also 
expected that treated cells in general, would present much less p-ERK than non-treated 
cells. 
After 24 hours of treatment with BAY 766, we observed that SK-Mel28 
scramble shRNA_BAY766 cells (high basal levels of TRIB2) are intensive stained for 
TRIB2 (red) and phospho-ERK1 (green). For non-treated cells (SK-Mel28 scramble 
shRNA_NT), small differences occur and we clearly can see both signals. 
For SK-Mel28 TRIB2 shRNA_NT cells the intensity of p-ERK fluorescent 
signal is weaker, and this loss of intensity increases for treated cells (SK-Mel28 
TRIB2 shRNA_BAY766) (Fig. 3.9). 
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This results confirm that TRIB2 signal is stronger in expressing TRIB2 cells 
and p-ERK is weak in treated cells without TRIB2. Surprisingly, TRIB2 treated cells 
present a higher p-ERK signal than expected.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 MAPK pathway is activated when TRIB2 is overexpressed 
Immunofluorescence visualization of p-ERK and TRIB2 after BAY766 100 nM 
treatment. (A) The signal for activated ERK is intense in cells that also contain high 
levels of TRIB2.(B) This signal is even more intense in cells that were not treated with 
BAY766. (C) and (D)The morphology of cells with low levels of TRIB2 is very specific 
and different from the TRIB2 ones. When this type of cell line is treated the intensity of 
p-ERK decreases. X63 
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The strong evidence that TRIB2 is playing an important role in activating the 
MAPK pathway, when cells are treated with MEK inhibitors, lead us to question the 
molecular details of this mechanism. As we have seen before, TRIB2 contains a 
specific motif for MEK1 binding, so we hypothesised that TRIB2 is directly 
interacting with MEK1. 
We used a common technique used to evaluate the interaction between two 
proteins, the co-immuno- precipitation assay (Co-Ip) described on methods section, to 
test this hypothesis. 
 
7. TRIB2 and MEK interact and form a protein complex 
 
We performed to different and independent assays (Exp1 and Exp2), in the first 
one we used a home-made TRIB2 primary antibody, in the second one we used a 
different antibody detailed described o n  materials and methods page. After probing 
with the first antibodies (TRIB2), we immune-precipitated the samples (magnetic 
beads), and probed in a western blot for Total-MEK protein detection. 
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As expected, there is a signal corresponding for total MEK in all cell types, all 
cell types contain MEK and TRIB2 proteins. However, in lanes were TRIB2 is over 
expressed (SK-MeL28 scramble shRNA; 293T TRIB2) this signal is much stronger in 
both experiments (Exp1-home made and Exp2 SCBT). (Fig. 3.10) 
This result demonstrates that TRIB2 interacts with MEK1.  
8. Confirmation of co-localization using confocal microscopy 
 
Previous results from CO-IP demonstrate that TRIB2 and MEK interact and 
form a protein-protein complex. We hypothesised that these two proteins would also 
co-localise. 
The cells when submitted to dual staining for MEK and TRIB2, reveal that 
there is a clear overlapping between the two colours green (TRIB2 staining) and red 
(MEK staining). As expected, this overlap (co-localization) happens in cells that over 
express TRIB2 (SK-Mel28 scramble shRNA_NT or SK-Mel28 scramble 
shRNA_BAY766). 
As it is not possible to completely knock down the total amount of protein, it is also 
possible to see the same overlapping in the cells with low levels of TRIB2 (SK- Mel28 
TRIB2 shRNA_NT and SK-Mel28 scramble shRNA_BAY766). However, this signal is  
weaker (Fig. 3.11) 
This result confirms that MEK and TRIB2 co- localize within the cell. 
 
Figure 3.10-TRIB2 and MEK form a protein complex in isogenic matched cell lines. 
To analyse the MEK-TRIB2 interaction, Lysates from two different isogenic cell 
lines, SK-MeL28 and 293T, were subjected to immune-precipitation using a 
homemade antibody against TRIB2 in experiment 1, and a commercial TRIB2 
antibody in experiment 2. Then, lysates were western blotted for MEK and β- actin. 
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Figure 3.11 - MEK and TRIB2 co-localize. 
Imunofluorescence visualization of total-MEK and TRIB2 after BAY766 100 
nM treatment. The signal for both proteins is overlapped, as demonstrated 
by the yellow colour in the merge panel. This phenomenon is more evident 
in cells that contain high levels of TRIB2. The strength of both signals 
between treated and non-treated cells in insignificant (A) and (B).  Although 
the levels of TRIB2 are low, it is possible to see that small amounts of protein 
are sufficient to overlap with MEK(C) and (D). X63 
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9. Cells that over express TRIB2 repress the transcription factor 
FOXO3a 
 
So far, we have observed that at the protein level, the increase of TRIB2 within 
the cell is critical to confer resistance to the MEK inhibitor BAY766. At this point, we 
also wanted to investigate if high TRIB2 expressing cells repress two of the most 
important transcription factors present in this pathway: FOXO3a and NF- Kappa B. DNA 
replication and recombination, DNA repair, chromosome segregation, chromosomal 
stability, cell cycle progression, epigenetic silencing, and regulation of gene expression 
are mediated through protein–DNA interactions. Thus, it is of principal importance to 
understand the significance of these interactions in driving a biological response.  
The first step consisted in choosing a promotor that FOXO3a is known to bind 
and activate: p27 promoter. Then we hypothesised if FOXO3a lacks the ability to bind the 
promoter, in the presence of an inhibitor. 
Input samples (left panel) were submitted exactly to the same procedure that 
FOXO3a ChIP samples, but these samples were not probed with FOXO3a antibody. 
These samples can function as a negative control. By comparing the FOXO3a ChIP 
with Input samples, we can clearly note that there is an increase in the signal for lanes 
293T GFP BEZ235 and 293T GFP BAY766 (TRIB2 non-expressing cells). On the 
other hand, in over expressing cell lines (293T TRIB2 BEZ235 and 293T TRIB2 
BAY766), the intensity of bands is similar to the control (input samples). 
This result indicates that in cells with low levels of TRIB2, FOXO3a has the 
ability to bind DNA (p27 promoter). When TRIB2 is highly expressed, FOXO3a is 
repressed (Fig. 3.12). 
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Figure -3.12- FOXO3a is repressed by over expression of TRIB2. 
Representative DNA gel following FOXO3a ChIP assay, after 24 hours post drug 
treatment. Protein-DNA complexes from 293T isogenic cell line were immune-
precipitated with FOXO3a antibody, as indicated. Input control has no antibody. 
After cross-link reversal, the co-immunoprecipitated DNA fragment corresponding to 
the FOXO3a promoter region was amplified by quantitative RT-PCRPCR using the 
appropriated primers and resolved in 2% agarose gels. N=3. 
TRIB2 cell lines present darker bands in comparison with input control 
 
Qualitatively, we saw that TRIB2 over expressing represses the transcription 
factor FOXO3a, and subsequently the transcription of the gene p27 via its promoter. 
Next, we decided to quantify the FOXO3a ChIP assay 
Calculating the fold change/difference between input (control) and the 
FOXO3a samples, allows to quantify the repression of FOXO3a. 
In cell lines exposed to BEZ 235 and BAY 766, it is possible to see a great 
difference in terms of fold change. This difference is not so significant in the cells that 
were not treated. This fact validates the theory that FOXO3a is being repressed 
(Fig.3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13-FOXO3a has more affinity to promoter with high levels of TRIB2 
293T GFP (White bars) and 293T TRIB2 (black bars) cells were treated with BEZ 235, 
BAY 766 or non- treated or 24 hours. Quantitative Real Time RT-PCR analysis for our 
p27 ChIP gels were normalised to inputs from each respective cell line endogenous 
control. All samples were normalized with GAPDH. N=4. Cells treated with BEZ 235 
are recruited to the promoter efficiently 
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10. TRIB2 over expressing cells have higher levels of NF-κB in their 
nucleus 
 
The next approach was to figure out if the TRIB2 over expression leads to the 
increase of NF-κB in the nucleus, because deregulation of NF-κB pathway is 
frequently observed in cancer cells and is associated with tumorigenesis and tumor cell 
resistance to cancer therapies, especially in melanoma. We suspected that NF-κB 
efficiency to bind the promotor would increase, in the presence of higher levels of 
TRIB2. 
To address this hypothesis, we performed a NF-κB ChIP assay in the same way 
that we did for FOXO3a 
DNA gel was made 24 hours post drug treatment (BEZ 235 and BAY766), NF-
κB ChIP assay reveals that the bands are more intense in the presence of high TRIB2 
expression (293T TRIB2:NT, BEZ 235 and BAY 766). The same is not valid for cells 
with low TRIB2 (293T GFP:NT, BEZ 235 and BAY 766), as these corresponding 
bands are much less intense in comparison with the Input control. NF-κB has more 
affinity to bind the SESTRIN 1 promoter, when TRIB2 is highly present in the cell. 
This data suggests that NF-κB is present in higher levels in the nucleus of 
TRIB2 over expressing cells (Fig. 3.14). 
 
 
 
 
 
 
 
 
 
 
Figure 3.14- NF-κB has more affinity to bind the promoter, when TRIB2 is present 
Representative DNA gel following 24 hours post drug treatment. Protein-DNA 
complexes from 293T isogenic cell line were immune-precipitated with NF-κB 
antibody, as indicated. Input control has no antibody. After reversal cross-link, the 
coimmunoprecipitated DNA fragment corresponding to the NF-κB promoter region 
was amplified by quantitative RT-PCR using the appropriated primers and resolved in 
2% agarose gels. N=3.TRIB2 cell lines present darker bands in comparison with input 
control. 
. 
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After NF-κB ChIP assay, we used the same layout to the FOXO3a ChIP assay 
to quantify this result (Fig.3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 NF-κB has more affinity to promoter with high levels of TRIB2 293T 
GFP (White bars) and 293T TRIB2 (black bars) cells were treated with BEZ 235, BAY 
766 or non-treated for 24 hours. Quantitative Real Time RT-PCR analysis for our 
Sestrin1 ChIP gels were normalised to inputs from each respective cell line endogenous 
control. All samples were normalized with GAPDH. N=3. The number of nuclear NF-
κB molecules is higher in non-treated cells that have high levels of TRIB2 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4. DISCUSSION
TRIB2 confers resistance to MAPK and mTOR1 inhibitors 
 
 
 
 
CHAPTER 4. DISCUSSION 
 
 
 
 
64 
 
 
CHAPTER 4. DISCUSSION 
 
1. Discussion 
 
Melanoma is one of the deadliest types of cancer. Although it is very easy to detect 
in early stages, melanoma in stage IV of progression can spread to other organs such as 
lungs and brain. These melanoma patients (stage IV), also resist to the traditional anti-
cancer treatments. It is very important to develop new strategies to fight against chemical 
resistance. This capability is due to the genetic background of melanocytes: this type of 
cells is prevenient from the neural crest during the embryonic development. The neural 
crest cells migrate extensively to generate a prodigious number of differentiated cell 
types78.  
In our Laboratory, we have investigated in which way tumour suppressors such as 
FOXO3a and P53 or oncogenes like RAS influences cancer formation and progression 
with particular attention directed towards resistance to anticancer treatment. 
In Previous studies, we have seen that the protein TRIB2 modulates resistance to 
traditional drugs like DTIC or new target inhibitors such as PI3K. TRIB2 is an oncogene 
overexpressed in melanoma, that acts through the negative regulation of FOXO. All these 
findings and the structural information that TRIB2 contains a specific MEK1 binding 
motif, lead us to hypothesised that TRIB2 could be a good candidate for mTOR and 
MEK inhibitory resistance, and play an important role in two most affected signalling 
networks in melanoma: the MAPK and PI3K/AKT pathways.  
It is currently unclear whether TRIB2 regulates mTOR, an important 
activator of AKT, in melanoma. Here, different isogenic cell lines were created and 
shRNA constructs were used to silence TRIB2 in cells with high endogenous levels 
of this protein. Rapamycin (mTORC1 inhibitor) treatment provides a simple and 
straightforward method to inhibit the mTOR signaling pathway and to study the 
influence of mTORC1 on the TRIB2-dependent mechanism of resistance. We found 
that expression of TRIB2 in the presence of rapamycin enhances cell viability. We 
concluded that TRIB2 confers resistance to mTOR inhibition via complex1 but not to 
mTORcomplex2. We observed that TRIB2 is not determinant to affect viability when 
cells are treated with a mTORC2 inhibitor (TORIN1). This evidence is reinforced, 
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when we knock down RICTOR a key structural protein from mTOR complex2. Since 
mTORC2 positive regulates AKT phosphorylation, we expected that loss of RICTOR 
results in mTORC1 blockage and AKT pathway disruption, raising cell death. This 
shows that TORIN is effective and TRIB2 is not participating in the mechanism of 
resistance through mTORC2  
AKT is a molecular target of mTOR and one of the most studied genes in 
melanoma research. We wanted to know what is the molecular mechanism, regulated 
by TRIB2, which confers resistance to mTOR inhibition via AKT. Although TRIB2 
does not affect the phosphorylation of Thr308, we conclude that TRIB2 functions as an 
adaptor protein that facilitates the phosphorylation of the Serine 473, recruiting mTOR 
and sub consequently the activation of AKT. Velasco et al. reported that TRIB3 
possesses a tumour inhibitory activity through the regulation of AKT pathway in breast 
cancer cells.50 Inhibition of TRIB3 increases tumorigenesis due to enhanced 
phosphorylation of AKT by the mTORC2 complex and subsequent inactivation of 
FOXO3. Homology between TRIB family members is high, so it is possible to speculate 
that TRIB2 and TRIB3 have opposite molecular functions and compete for the same 
substrate (mTORC1) 
High and low expression levels of TRIB2 correlate with immature and 
mature subtypes of human T-ALL, respectively, and associate with MAPK 
pathway.51 Here, we identified TRIB2, a pseudokinase protein, as an important 
MAPK downstream effector in melanoma: we observed that MEK and TRIB2 co-
localize and also confirmed that TRIB2 has the capability to interact with MEK and 
form a protein-protein complex, suggesting that this interaction is important to cells 
resist treatment. Our results, highlight what has been described in literature. TRIB 
proteins have previously been reported to bind to MEK in leukemia cells: TRIB1 
and MEK1 interaction is required for Trib1-induced leukemogenesis52.  
Besides the directly interaction with MEK, we also wanted to know how does 
TRIB2 confers resistance to MEK inhibitors and unveil its mechanism. We examined the 
functional importance of MEK-dependent TRIB2 expression. We submitted cells to drug 
time courses with BAY 766, a potent MEK inhibitor and analysed cell viability and 
protein expression. TRIB2 regulates the proliferation of developing thymocytes51 Jiayi 
Wang and Junhao Mao reported that TRIB2 is critical for liver cancer cell survival53 and 
transformation. These ideas converge with our first conclusion, TRIB2 is up regulated in 
melanoma cells (SKMl28 and G361) and inhibition of TRIB2 expression (knock down) 
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decreased cell numbers and cell proliferation, in the presence of a MEK inhibitor. One 
of the TRIB2 expression consequences is that phospho-ERK increases in cells, keeping 
the pathway activated. When cells are treated with a MEK inhibitor, BAY766, MEK 
function is blocked and consequently ERK phosphorylation decreases, as expected. 
However, when we looked to the control (total-ERK) we did not expect that some 
variations occur post BAY766 treatment. We conclude this is a consequence of 
experiment limitations. We should perform this assay with a proper number of 
repetitions (N=3) to confirm these results, as well as study other different markers and 
key regulators of MAPK pathway must be evaluated, since ERK is not an exclusive 
marker of this pathway being active. 
Qualitatively, we saw that TRIB2 over expressing represses the transcription 
factor FOXO3a, and subsequently the transcription of genes via pP27 promoter in the 
presence of inhibitors. 
A NF-κB increase is associated with inflammatory responses that favours the 
tumour development and progression. Kloster et al shows that the ability of cAMP to 
potentiate the induced activation of NF-κB requires the activity of MEK for the 
inhibitory effect of cAMP on DNA damage-induced cell death54. We demonstrate that 
TRIB2 over expressing cells have more affinity to recruit NF-κB, suggesting that this 
transcription factors concentration is higher in the nucleus of resistant cells 
Altogether, our study uncovers a novel regulatory mechanism underlying inhibitory 
resistance output for melanoma, and suggests that TRIB2 functions as a signalling nexus 
to integrate the MAPK and PI3Kpathways in cancer cells (figure 4.1). 
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Figure 4.1-Mechanism in which TRIB2 regulates the resistance for cells treated with 
MEKor mTOR inhibitors. 
We propose that post mTOR inhibition, TRIB2 has the capacity to function as an 
adaptor protein. It binds AKT and recruits mTORC1 that phosphorylates AKT in 
residue Ser473, a requesit for full activation. 
TRIB2 is also essential in the mechanism of MEK inhibition resistance. TRIB2 forms a 
protein-protein complex with MEK activating the MAPK pathway. NF-KB has high 
affinity for P27 promotor in TRIB2 expressing cells. FOXO3a is repressed in this type 
of cells after drug inhibition 
 
2. Future Directions 
 
Over the last decade, knowledge of the two most important molecular signalling 
networks in melanoma, MEK and AKT pathways, has greatly progressed. This is a 
project that contributes with new findings which will be useful in future basic and 
translational research leading to new therapeutics insights on metastatic melanoma 
resistant treatment.  
In the future is possible to reinforce the findings of this project. We could start 
to study the impact of TRIB2 expression in different cell lines and repeat the expression 
analysis for ERK and for different markers (MEK, downstream targets of ERK, etc.) 
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Cellular abundance of transcription factors is an important determinant of 
their regulatory activities. It is crucial to understand how these proteins control gene 
expression. To complete the analysis of transcription factors modulated by TRIB2 in 
MAPK and PI3K pathways, it would be interesting to measure the affinity to bind 
promotors or track expression of different genes. It is possible to do such analysis 
repeating Chip, use a gene reporter assay (Luciferase) or EMSA. We also can track 
when these transcription factors are in the nucleus or cytoplasm performing 
immunostaining assays.  
We should expand our studies to in vivo and clinical samples. We have very 
interesting conclusions about what happens in vitro, that must be emphasised with the 
information prevenient from protein expression analysis, RNA and DNA in clinical 
samples. A Knock out animal model would also be useful to evaluate drug treatment 
resistance phenotypes. 
Nowadays, there are in clinical trials, melanoma patients being submitted to 
combined therapy with MEK and RAF inhibitors. Some of these patients´ tumours 
bypass cell death, so it would be interesting to test in vitro if TRIB2 participates in the 
molecular network that origins this resistance 
TRIB2 can be established as a predictive biomarker capable and help to 
stratifying cancer patients into responders and non-responders to melanoma 
therapeutics. New insights will establish TRIB2 as a molecular target in personalized 
medicine. This way, new inhibitory compounds will be design against this protein to 
treat melanoma.   
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